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Abstract 
 
Chitosan-Triphosphate Nanoparticles 
There is a widespread interest in the use of nano-carriers for drug delivery and 
chitosan is one of the most sought-after components for designing biocompatible 
nanoparticles. 
Here, using a rational experimental design, I have studied the influence of a 
number of variables (pH, concentrations, ratios of components, different methods of 
mixing) in the preparation of chitosan/triphosphate (CS/TPP) nanoparticles and in their 
coating with hyaluronic acid (HA). The aim was to minimise size polydispersity, 
maximise zeta potential and long-term stability, and control the average nanoparticle 
size. As a result, three kinds of optimised nanoparticles have been developed, two 
uncoated and one HA-coated. Their toxicity on fibroblasts and uptake by macrophages 
have been evaluated. Experiments showed the beneficial character of HA-coating in the 
reduction of toxicity (IC50 raised from 0.7-0.8 mg/mL to 1.8 mg/mL) and suggested 
that the uncoated chitosan/TPP nanoparticles had toxic effects following internalisation 
rather than membrane disruption. Uptake tests were performed after the conjugation of 
fluorescein isothiocyanate (fluorescent label) with chitosan. The nano-carrier can be 
produced in future for the delivery of short sequences of RNA (e.g. siRNA), be 
trackable and rather have the ability to specifically bind to target cells. 
 
Chitosan-Triphosphate microparticles 
Monodisperse microparticles were produced using the Inotech® encapsulator 
exploiting the gelation between chitosan and TPP. The target of 300 µm size was 
obtained through optimising several parameters (nozzle oscillation, nozzle diameter, 
pH, concentrations, flow rate, electrostatic charge). TPP was chosen for its non-toxicity 
and fast gelling ability. The method was mild and did not require organic solvents or 
toxic cross-linking reagents. These particles will be used in future experiments to 
embed hydrophobic actives, proteins or living cells. 
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1 Introduction. Background and scope of the thesis 
1.1 What is chitosan? 
Chitosan (a copolymer of β-(1→4)-linked D-glucose-2-amine and N-acetyl-D-
glucose-2-amine) is a versatile biomaterial derived from chitin (essentially poly(β-1,4-
N-acetyl-D-glucose-2-amine)) (Fig.1-1), which is one of the most abundant natural 
polysaccharides. Chitin is found in the cell walls of microorganisms such as yeasts or 
other fungi, in the exoskeletons of crustaceans and insects and in several other 
specialized organs such as the beaks of cephalopods.  
In order to obtain chitosan, the removal of the acetyl groups is performed with a 
concentrated solution of NaOH avoiding depolymerization or production of undesired 
species. An alternative treatment was developed to avoid large use of NaOH, i.e. chitin 
is directly mixed with NaOH in powder at a weight ratio of 1 to 5, then at a temperature 
of 180°C the deacetylated chitosan is obtained by extrusion
1
; this procedure is eco-
friendly due to the absence of waste water. The X-ray diffraction studies prove that 
chitosan has a orthorhombic crystallization form
2
 with the three dimensions 
respectively of 0.828, 0.862 and 1.043 nm 
3
. The degree of crystallization is related to 
the number of acetyl groups, these groups promote hydrogen bonds decreasing the 
chain mobility and modulating the sorption performance
4
. Chitosan is a biocompatible
5, 
6
 linear polymer that has low immunogenicity property, it has a ample range of 
applications
7-10
; the biocompatibility is directly proportional to the degree of 
deacetylation (DD), indeed the higher the content of amino groups in the backbone and 
the lower will be the toxicity of the resultant polymer
11
. The high percentage of 
nitrogen in chitosan (6.89%) gives a large number of groups that could be used for 
chemical modification; the physical properties depend on the type and the degree of 
substitution on primary amine. 
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Figure 1-1. Chitosan, a copolymer of β-(1→4)-linked D-glucose-2-amine and N-acetyl-D-glucose-2-
amine 
 
The nitrogen contained in chitosan is in the form of primary aliphatic amino groups 
and therefore, it undergoes reactions typical of amines, the most important being N-
acylation or alkylation and Schiff’s reaction12.  
It is noteworthy that, although all characterized by the generic name of “chitosan”, 
polymers with different properties are obtained through the deacetylation of chitin, 
which is often followed or accompanied by depolymerisation; different types of 
chitosan are obtained with varying the molecular weight (MW) and the charge 
density
13
.  It is therefore essential to characterize chitosan samples at least in terms of 
average molecular weight and degree of deacetylation, in order to ensure 
reproducibility in the experimental results; the MW can be determined by viscosimetry 
or static light scattering, and the DD by infrared spectroscopy, by colloid titration or by 
1
H-NMR. The deacetylation reaction can be performed as a heterogeneous
14
 or 
homogeneous
15, 16
 process, the first method gives chains with non uniform block 
copolymers of D-glucosamine and N-acetyl-D-glucosamine, the second method results 
in a homogeneous deacetylation of the chains; in the two cases the physicochemical 
properties appear to be different. It is preferable to have randomly distributed acetyl 
groups in order to compare easily chitosans with different MWs
16
.  
A few mammalian enzymes, such as α-amylase or lysozyme can degrade chitosan, 
therefore it can be generally regarded as a degradable material
17
, its oligomers activate 
macrophages and moreover the hyaluronan synthesis is stimulated
12
. Tumor cells 
recognize the polycation; this gives a chance to have a selective vehicle. Chitosan has 
been extensively employed in the development of micro- or nano-carrier structures
18
, 
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with a specific focus on the use of complex inclusive of active principles such as 
nucleic acids, e.g. small interfering RNA (siRNA)
19
, or proteins
20
 having enzymatic 
activity
21
. It is noteworthy that the activity of these nano-carrier systems towards a 
biological target may be affected by chitosan biological properties, for example its 
anticancer activity
12, 22
. 
The distribution charge in the polymer is highly positive, this allows the formation 
of complexes in presence of polyanions
12
, moreover the adsorptive characteristic 
depends on the crystallinity and on the number of amines free to interact
23
. The safety 
and the non-toxicity is an advantage
24, 25
 and the mucoadhesive property is another 
interesting characteristic of chitosan
26
.  
The chitosan mucoadhesion is strictly correlated with the degree of deacetylation, 
and this property change following the variation of pH
27
 or of ionic strength values of 
the system
26
. Mucoadhesion and swelling properties could be improved by increasing 
the acid dissociation constant (pKa) of the biopolymer
26
, which can be modified by 
permanent substitution of the primary amines. The interaction of chitosan with mucosal 
surfaces is possible since the cells are negatively charged; this is due to the presence of 
sialic acid on the surface membrane, which with its negative charge permits binding 
and transport of positively charged molecules
28
. In addition, chitosan exhibits a 
permeation enhancing effect by opening the epithelial tight junctions; this was 
confirmed since the polymer is able to decrease in a reversible way the transepithelial 
electrical resistance (TEER) among cells without damaging them or lowering their 
functionality
29
. 
The purity of chitosan must be constantly checked, since the biopolymer is subject 
to several types of contamination during the food processing of chitin (e.g. protein 
contamination). Raw chitosan bought from different suppliers may differ in purity, due 
to its source, season, and conditions of the chemical deacetylation process
30
. 
Protein contamination must be avoided in formulations prepared for biomedical 
applications. Thus, a highly purified chitosan is desirable and various purification 
protocols were reported in literature
30, 31
. 
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1.2 Chitosan applications 
1.2.1 Chitosan potentiality 
Chitosan has been studied extensively in industry for its enormous potentials as an 
ingredient for foods
8
, porous beads for bioreactors, for hair care products, as a 
coagulant for waste-water treatment
10
, in controlled release systems, wound healing
32
, 
cell encapsulation, tissue engineering
33
 (e.g. implants for the cartilage
34
) and as a drug 
carrier
35
. Chitosan serves as a successful candidate for various medical applications due 
to a number of reasons. It is a clotting agent and absorbs liquids, important aspects for 
wound healing; degradation products have no toxic effects and since it is 
depolymerised by lysozyme can be designated as a bioerodible system to deliver 
actives principles
36
, through nasal
37
, skin, intestinal, buccal and vaginal epithelia
38
; 
moreover higher is DD and more enhanced will be the absorption
37
, this is due to the 
reduction of the rate of clearance, with a consequent prolonged contact time. In 
addition, the polymer possesses an antimicrobial activity
39
, characteristic that was 
improved when the chlorhexidine, an antiseptic, was loaded
40
 in chitosan microspheres. 
Chitosan induces the macrophage activation
41
, this involves the production of 
interleukin-1 (IL-1) and nitric oxide, in addition to the chemotaxis response
42
. It was 
also demonstrate that chitosan influences the hydrogen peroxide generation
43
. 
 
1.2.2 Nanoparticles thought for gene delivery 
Chitosan has a greater ability to complex DNA or RNA and form nano-complexes 
compared to other cationic polymers
44
, the strength of complexation is influenced by 
salt concentration, pH, polymer charge density and molecular weight
45
. The biopolymer 
protects from nucleases activity
19, 45
 and allows the cellular adhesion, the internalisation 
of the nano-carriers and escape from the lysosomes
46
 in the cytoplasm. Lysosomotropic 
agents, ie chloroquine, were used in order to facilitate the nanoparticles escape and 
preserve DNA or RNA activity but they can bring undesirable side effects in vivo
44, 47, 
48
. The transfection efficiency of chitosan-based nano-vehicles is cell-type dependent, 
there is no toxicity respect to other more toxic particles like Lipofectamine
TM
, a 
cationic lipid; unluckily the transfection efficiency of chitosan nanoparticles is lower 
than Lipofectamine
TM
 
44, 49, 50
. For an effective transfection, it is important not solely 
the internalization but successively as well the endo-lysosomal escape. Chitosan was 
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chosen since it can exploit its buffer capacity in a restricted interval of pH values (5-7), 
and promote after 72 hours the rupture of the endosomes with the consequent escape in 
the cytosol
51
. Moreover, for medical purposes, once produced the nanoparticles, they 
have to possess stability for long period of time, and so it is highlighted the importance 
of the lyophilization by freeze-drying. This procedure must not cause loss in activity 
and aggregation must me avoided, it is for these purposes that cryoprotective agents 
ought to be used (ie mannitol, sucrose)
52
 during the process of drying. 
 
1.2.3 Microparticles for proteins and cells delivery 
The chitosan is used for microparticles production to overcome to problems of 
insolubility and hydrophobicity of several actives principles, adversely the polymer 
itself has not good stability under direct compression
12
. This problem was solved using 
excipients facilitating the compression
53
 like magnesium stearate
54
. Chitosan is used as 
an efficient excipient in the gastrointestinal tract for delivery of proteins
55
 that 
otherwise would have been destroyed by several enzymes, or would have not been 
intestinally absorbed
56
. 
 
1.3 Chitosan-Tripolyphosphate interactions 
1.3.1 Complexation 
An ionotropic gel is produced in a process of physical cross-linking between a 
polycationic (in this case a polyelectrolyte) and a polyanionic (in this case a multi-
charged ion) component. The chosen polyanion is the sodium triphosphate (TPP), it  is 
largely used in food industry, in detergents and biomedical applications for its non-
toxicity
57
 and fast gelling ability
30, 58
. 
 
 
Figure 1-2. Triphosphate anion, it has three charges when the ph is between 3 and 5.5. 
 
   Chapter 1                                                                                                    Introduction 
 
18 
 
The interactions between chitosan and TPP depend on the ionic strength and pH of 
the solution. The complexation is most effective when the charge densities of the two 
combined partners reach a maximum, therefore, due to the above pH dependence, the 
pKa values of both chitosan and TPP must be carefully taken into consideration. The 
pKa of the chitosan amine groups ranges between 4.5 and 8. Therefore, it is fully 
positively charged below 4, and completely neutral above 9. The TPP pKa values are 
pK1=1, pK2=2, pK3=2.79, pK4=6.47, pK5=9.24. 
 
 
Figure 1-3. Chitosan and TPP behaviour at different pH values. pH affects the degree of ionization of 
chitosan and the charge number of TPP, pyrophosphate and phosphate. Each sphere shows where the 
degree of ionisation varies considerably for small variations of pH (buffer area); in these points, the pH 
corresponds to the pKa. Adapted from Shu et al, 2002
59
. 
 
It is imperative to maintain a pH value lower than 5 in order to have a chitosan fully 
protonated, on the contrary pH of 3 is the minimum value for the TPP to possess three 
charges. Therefore, the complexation between chitosan and TPP and the resultant 
crosslinking density is pH dependent
60
, since their charge density depend on pH values 
(see table 1-1); for an acceptable and stable complexation the values must range 
between 3 and 5.5 (Fig. 1-3). 
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Table 1-1. Varying the pH value, the percentage of protonation in the glucosamine units constantly 
change, and at the same fashion the TPP negative charges are range from 3 to 4 charges. 
 
 
Above pH 6, chitosan charge density is not sufficient to prevent falls and to provide 
good complexation behaviour; whereas below pH 4 the charge density of TPP is too 
low to keep at least 3 negative charges. 
The linkage of chitosan amines with TPP molecules can be confirmed by infra-red 
spectroscopy; the ionotropic complexation is a mild method and does not require 
organic solvents or toxic cross-linking reagents (e.g. glutaraldehyde)
61
.  
 
 
 
 
 
 
 
 
 
Figure 1-4. Ionotropic complexation between the free charged ammines and the three negative charges 
of the TPP. 
 
At a pH lower than 4 pH, the chains of chitosan adopt a more extended 
conformation and form a complex with TPP in a ladder-shaped structure
62
, which does 
not provide elastically active cross-links. Crosslink density is a key factor for stability, 
swelling behaviour and drug release. Generally, molecules entrapped in biopolymer 
matrices can be released by three mechanisms: desorption from the external particle 
surface; diffusion through the swollen matrix; or by erosion of the biopolymeric 
network
63
. Drugs with minute sizes can easily use the first two mechanisms, but 
macromolecules require the erosion mechanism once entrapped. Gan et al, furthermore 
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noticed that during the swelling behaviour (loss in particle density), there was no 
structural break in smaller particles but rather a swelling with loss in structure 
compactness and breaking of cross-linkage, followed by material degradation
63
. In the 
case of nanoparticles produced by ionotropic complexation, the MW strongly 
influences the particle size, indeed higher is this value and higher will be the 
dimensions of the nanoparticles
19
. 
 
1.3.2 Effect on the complexation and release of actives principles 
from a chitosan/TPP-based matrix  
The release of actives principles from a gel matrix depends on chitosan MW and 
DD
62, 64
, concentrations, chemical characteristics and charge density of the loaded 
molecules, viscosity, pH
65
 and ionic strength of the solutions in which the matrix is 
immersed, chitosan/TPP ratios
30
 and degree of crosslinking
66
. The increase in viscosity 
involves the formation of denser chitosan/TPP mesh, a higher crosslink density and a 
smaller ability of swelling with a consequent reduction in drug release. In addition, 
keeping constant the MW but increasing the DD will imply an increase in loading 
capacity, higher compactness and retardation in the release
64
. Moreover, it was 
demonstrated that a lower chitosan/TPP ratio could favour the entrapment of 
macromolecules
63
. In the study with microparticles, the high molecular weight 
( 500g/mol) is selected in order to obtain high level of protein entrapment and burst 
effect reduction
30
. 
 
1.4 Scope of the thesis 
During this project, chitosan was exploited in two different ways, which follow a 
similar preparative approach: the use of ionotropic gelation amid chitosan and TPP in 
order to form a) a nano-vehicle system and b) a micro-particulate system. 
The aim of the first part of the project was the production of a bespoke nano-carrier 
for an effective gene delivery system. This delivery system had to be trackable and also 
must have the ability to specifically bind to target cells due to the presence of an 
external shell that recognizes unique cell-surface receptors thus enhancing the degree of 
therapeutic success by selective targeting.  
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Figure 1-5. Hypothetical nanoparticle structure composed of inter/intra-connected linkages of chitosan. 
 
The nano-carrier had to be capable of loading different types of actives during 
(embedding) or after (adsorption) the complexation between chitosan and TPP; some 
preparation will have fluorescently-labeled chitosan in order to monitor the fate of the 
nano-carriers in vitro. The actives principles would have been introduced and the 
effects of the delivery studied. Finally, the nanoparticles must increase the cellular 
uptake and protect the actives principles from intracellular degradation. 
The study of the interactions between chitosan and sodium tripolyphosphate must 
aim to identify the most important parameters and to optimise them in view of 
improving the complexation and obtaining the most stable and reproducibly behaving 
nanoparticles. 
The aim of the second part of the project was the production of chitosan-based 
microparticles using the encapsulator, medical device for active principles entrapment. 
The ionotropic gelation was used to form the particles and a number of variables were 
studied in order to obtain the most monodisperse microparticles. The target was to 
obtain particle size of 300 µm and to embed in these proteins or living cells.  
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2 Chitosan/TPP and chitosan/TPP-hyaluronic acid 
nanoparticles 
2.1 Summary 
Gene medicine utilizes nucleic acids with the aim of restoring or shutting down a 
specific cellular function
1
. The formulation of negatively charged nucleic acids with 
various polycations into micro- or nanoparticulate structures (complexes) through 
electrostatic interactions has proven useful for creating non-viral delivery vehicles
2
 
where nucleic acids are physically condensed into small particles and should facilitate 
their cellular binding and uptake. In an ideal vehicle,   
a) the nucleic acid is complexed in a reversible fashion,  
b) the nature of the carrier does not depend strongly on the amount and nature of the 
nucleic acid,  
c) the surface of the carrier is functionalisable with “stealth” groups and targeting 
groups can be added too. 
Chitosan (CS) was selected as a building block, because  
1) its complexation with poly/oligoanions is reversible (at acidic pH),  
2) can form nanoparticles with a variety of polyanions, which can be used as a 
second building block to provide appropriate mechanical and transport properties to the 
nanoparticle (which therefore do not depend on the nature and concentration of the 
nucleic acid),  
3) can impart a net charge to the particle surface, which allows its easy 
fictionalization via polyelectrolyte adsorption. 
A rational study was performed for the optimisation of size, size dispersity and 
stability of nanoparticles formed by chitosan and sodium triphosphate (TPP), the anion 
used as a cross linking agent. After optimisation the nanoparticles were coated with 
hyaluronic acid.  
Furthermore, a study of cytotoxicity and internalisation of the best nanoparticles 
on/in two model cell lines: non-phagocytic fibroblasts and phagocytic macrophages. 
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2.2 Introduction 
The elastic, solid-like character of nanoparticles (→ morphological stability and 
control over diffusion kinetics of entrapped molecules) and the possibility of 
introducing appropriate surface functionalities (→ biological targeting) are at the basis 
of the widespread interest for this class of colloidal objects in the field of controlled and 
targeted release. 
Nanoparticles can be rendered responsive, linking their performance to physico-
chemical or biological stimuli
3
, for example coupling morphological transitions and 
thus changes in release kinetics or in uptake by cells to changes in pH or temperature, 
to the presence of oxidants
4
. 
We will not discuss further the general applications of nanoparticles in 
biomedicine
5
; we will, on the other hand, specifically focus on a few key points that are 
essential for their structural design. 
a) nanoparticle bulk: a colloidal drug carrier is generally internalized through 
endocytosis, ending up in endosomes characterized by an increasingly aggressive 
environment with time. In most cases, it is desired that the carrier escapes from these 
compartments; a commonly adopted strategy is based on the use of weakly basic groups 
that, due the acidity of endosomal compartments, can be protonated, thereby increasing 
the local osmotic pressure up to the collapse of the endosomal membrane. 
b) nanoparticle surface: in the absence of a specific target, the surface composition 
should allow a prolonged circulation in the body fluid of choice, i.e. it should be 
“stealth” enough to allow the diffusion of the nanoparticles throughout the site6; to 
increase the stealthiness, the surface should be wettable by water in order to obtain a 
complete camouflage (“if you want to be invisible, look like water”)7. The evasion of 
the nanoparticles by macrophages is obtained avoiding the protein adsorption and 
eluding the opsonization and the complement activation
8
; indeed it was demonstrated 
that small neutral nano-vehicles have longer half-life circulation than the same type of 
particles with anionic surface
9
. Among the polymer structures that could be used for 
providing this protein-repellent character, besides the ubiquitous poly(ethylene glycol) 
(PEG), one could mention dextrans
10
, poly(N-vinyl pirrolidone)
11
, poly(glycerol 
methacrylate)
12
 and glycosoaminoglycans, such as heparin
10
 or hyaluronic acid (HA)
13
. 
c) degradability and biocompatibility: at the end of its life cycle, a carrier should be 
degraded to excretable or metabolisable products, showing negligible cytotoxicity 
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throughout the life cycle. It is noteworthy that in this process the interactions between 
cells and nanoparticles are mostly dependent on the nanoparticle surface composition, 
and specifically on charge, but also on their size
14-16
. 
We have here focused our attention of chitosan-based nanoparticles. Probably, the 
most popular way to produce chitosan-based nanoparticles is its ionotropic gelation 
with a small polyanion, sodium tripolyphosphate, which is characterized by a triple 
negative charge throughout the physiologically acceptable pH range
17, 18
. This form of 
polyelectrolyte complexation can be limited within a nano-size if one of the partners is 
present in large excess and if appropriately low concentrations are employed. 
It has been initially found that concentrations below 2 mg/mL and 0.4 mg/mL 
respectively for TPP and chitosan, should be used, in order to avoid the formation of 
large aggregates, with chitosan/TPP mass  ratios possibly not exceeding 15-20/1
17
; 
larger chitosan/TPP ratios yielded particles with larger size (but obviously lower cross-
linking density) and zeta potential
17, 19, 20
. Kumacheva et al. have refined these initial 
studies, investigating the effect of chitosan fractional precipitation and deacetylation as 
means to increase its TPP-binding efficiency
21
. 
We have here expanded the findings of Kumacheva, using a highly deacetylated 
chitosan and focusing on the different variables that may affect the chitosan – TPP 
complexation: not only the chitosan/TPP mass ratio, but also the pH, which determines 
chitosan protonation degree and therefore both its binding ability and its self-
association, and the volume ratio between the solutions. The latter parameter is of often 
neglected significance: if the complexation kinetics is of the same order of magnitude 
as or quicker than the mixing of the two solutions, it is likely to have a kinetic control 
over the properties of the final nanoparticles. 
The main method to vary the size and modulate the reaction kinetics is to vary the 
NH3
+
/O
-
 charge ratio (free chitosan amines/TPP oxygen negatively charged), the ratio 
can range from 6 to 0.5
17, 20, 22-24
; this modulation has a consequent effect on the ζ-
potential (range +20/+60mV), on the loading capacity
17
 and on cellular transfection
24
. 
The scope of this part of our study was the development of chitosan/TPP 
nanoparticles optimized against the following parameters:  
a) reasonably narrow size dispersity and size control, possibly producing <200 nm 
(“small”) and 200-400 nm (“large”) nanoparticles, in order to later study the effect of 
size in the interactions with cells,   
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b) high zeta potential, possibly with a narrow distribution, in order to obtain both a 
good electrostatic stabilisation and the possibility of a surface functionalisation through 
polyelectrolyte deposition,  
c) stability of both size and zeta potential in water and/or buffer, in order to ensure 
long-term storage 
d) stability of pH when the nanoparticles are stored in unbuffered water solutions. 
Drifts in pH would signal ongoing complexation (or de-complexation) phenomena: the 
basicity of chitosan primary amines can indeed be influenced by the density of 
immobilized negative charges present nearby, and correspondingly we expect an 
increase in pH for increasing complexation. 
Having therefore optimised the design of these nanoparticles, we have studied the 
conditions for the adsorption of hyaluronic acid on their surface, with the aim to 
produce HA-coated nanoparticles; these colloidal carriers could at the same time 
present “stealth” character and allow targeting of HA receptors25. 
These coated nanoparticles would present a bulk mostly composed of TPP-cross-
linked chitosan and a surface where HA would concentrate, thus providing a negative 
zeta potential (Figure 2-1), and possibly a “stealth” character and the possibility to 
target HA receptors. 
Finally, both uncoated and coated nanoparticles have been characterized not only in 
terms of their physical properties, but also for their cytotoxic effects on two model cell 
lines: non-phagocytic fibroblasts and phagocytic macrophages. Specifically, we have 
investigated their effects on cell viability and on the integrity of cell membrane. 
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Figure 2-1. Graphical view of the structure of HA-coated chitosan/TPP nanoparticles, where TPP is 
present in low concentrations in the bulk of the nanoparticles, acting as a cross-linker and bridging 
between positive charges on the chitosan chains. The negatively charged HA complexes chitosan on the 
external part (the surface) of the nanoparticles, although a certain degree of diffusion in the bulk is 
possible.  
 
2.3 Experimental section 
2.3.1 Materials 
Pentasodium triphosphate (Fluka), 1N hydrochloric acid, DMSO, 1N sodium hydroxide 
(Aldrich), fluorescein isothiocyanate (FITC) (Sigma), glacial acetic acid and sodium 
acetate (VWR BDH Chemicals, Poole, UK) were used as received. 10 mM Phosphate 
buffered saline (PBS) was prepared from appropriate tablets (Oxoid, Basingtoke, UK). 
Chitosan (“low MW”: Cat. No. 448869, Aldrich) was used after purification as 
described hereafter. Hyaluronic acid with average viscosimetric molecular weight of 
15*10
3 
g/mol and 360*10
3 
g/mol was obtained from Medipol (Lausanne, Switzerland). 
The two single strand DNAs (Metabion, Martinsried, DE) were used as received, 5'-
CGG TGT GTC TGT CGG TTG-3' (MW=5569 g/mol) and 5'-GGA TCC TAA TAC 
GAC TCA CTA TAG GCA GTA ACT ATA ACG GTC CTA AGG TAG-3' 
(MW=16004 g/mol). 
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The QuantiPro BCA assay kit was supplied from Sigma, Gillingham, UK: QuantiPro 
Reagent QA (M3810) was a solution consisting of sodium carbonate, sodium tartrate, 
and sodium bicarbonate in 0.2 M NaOH, pH 11.25. QuantiPro BCA QB (M3685) was a 
4% (w/v) bicinchoninic acid solution, pH 8.5. Copper (II) sulfate, Pentahydrate 4% 
Solution (C2284) (Reagent QC) was a 4% (w/v) copper (II) sulfate, pentahydrate 
solution. 
Protein Standard Solution (P0914) was supplied in 10 flame-sealed glass ampoules, 
each containing 1.0 ml of a solution consisting of 1.0 mg/ml bovine serum albumin in 
0.15 M NaCl with 0.05% sodium azide as a preservative. 
Double distilled Milli-Q water was produced using in series an ELGA Docking Vessels 
DV35 and a Milli-Q Gradient A10 System. 
 
2.3.2 Physico-chemical characterisation 
Dynamic Light Scattering (DLS) and zeta potential measurements were performed on a 
Zetasizer Nanoseries ZEN3600 (Malvern Instruments) equipped with a solid state 
HeNe laser (  = 633 nm). All the samples were analyzed at an angle of 114° and a 
temperature of 25°C. AFM measurements were performed on nanoparticles deposited 
on a mica surface from dispersions in deionised water using a MPF-3D instrument 
(Asylum Research). Viscosity measurements were performed on a 0.25 M acetic 
acid/0.25 M sodium acetate solution using a falling ball automated microviscometer 
(Anton Parr) at 25 C equipped with a 1.6 mm internal diameter capillary tube at an 
inclination angle of 30 degrees. The visosimetric average molecular weight was 
calculated assuming the parameters of the Mark-Houwink equation to be equal to K = 
1.57 x 10
-5
 L.g
-1
 and a = 0.79 
26
. 
1
H-NMR spectra were recorded on JEOL EX270 270 MHz NMR spectrometer (Bruker 
Avance 270, Coventry, UK). Infrared spectra were recorded on a Tensor 27 in ATR 
mode. UV-Vis spectra were recorded on a Perkin Elmer Lambda 850 spectrometer. 
Fluorescence measurements were performed using a Perkin Elmer LS55 luminescence 
spectrometer equipped with a xenon discharge lamp; the cuvette used was made of 
quartz glass. 
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2.3.3 Purification of chitosan 
5 g of chitosan (MW 495, DD 90%) were dissolved in 400 mL of a 2% w/v acetic acid 
solution in double distilled water. Complete dissolution was achieved after 16 hours of 
stirring. The solution was then boiled for 15 minutes in order to denature and 
precipitate any proteic contaminant. 
The mixture was then centrifuged for 10 minutes at 4500 rpm; the supernatant was 
removed then and filtered through 1 μm pore size filters. The pH of the solution was 
then corrected to 9 with 1N sodium hydroxide, in order to precipitate chitosan from the 
aqueous phase. After centrifugation, the precipitate was redispersed and again 
sedimented via centrifugation twice, always using water at pH = 9 as a dispersing 
medium. The procedure was repeated with Millipore water until the pH and 
conductivity values reached the values of pure water. The sample was freeze-dried 
(yield of the overall procedure = 86%) and stored at 4°C. 
1
H-NMR (2%w/w HCl/D2O): = 2.3 – 2.4 (acetamide CH3), 3.4 – 3.6 (CH-NH2), 3.8 – 
4.4 (two broad peaks comprising CH-NHCOCH3 and all other non-anomeric protons), 
5.15 - 5.3 (anomeric protons) ppm. 
ATR-IR (thin film): 3500-3000 (  OH and NH2), 2875 (  CH), 1647 (amide I), 1588 
(amide II) 1380, 1320, 1063, 1030 cm
-1
. 
Colloid titration was performed in a 0.02 M acetate buffer/0.1 M NaCl at pH 4.5, which 
was used as the solvent for chitosan and poly(styrene sulfonate) (PSS) and toluidine 
blue (a cationic metachromatic indicator). 2 ml of 5*10
-3
 mg/ml chitosan solution were 
added of 20 µl of 0.03% toluidine blue O solution and then titrated with a PSS solution 
1*10
-3
 M in sulfonate groups, recording the ratio of the absorbance values at 635 and 
600 nm. 
Degree of deacetylation: before purification 91.01 mol % (
1
H-NMR: ratio between 
acetamide protons and anomeric protons, Fig. 2-23), 87.50 mol % (IR: ratio between 
the absorbance values at 1655 and at 2875 cm
-1
), 91.20 mol % (colloid titration); after 
purification: 92.02 mol % (
1
H-NMR, Fig. 2-24), 85.4 mol% (IR), 89.70 mol % (colloid 
titration). 
Intrinsic viscosity and viscosimetric average molecular weight: before purification 
[ ] = 0.493 L/g, Mv = 492*10
3
 g/mol; after purification [ ] = 0.481 L/g, Mv = 477*10
3
 
g/mol. 
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Table 2-1. Degree of deacetylation, MW, intrinsic viscosity before and after purification. 
 
 
Assessment of protein content: The assay consists of mixing 1 part of a protein 
sample with 1 part of the prepared QuantiPro Working Reagent. The protein sample is a 
blank, a protein standard, or an unknown sample. The blank consists of a buffer 
solution with no protein, a protein standard of a known concentration of protein, and an 
unknown sample is the solution to be quantified. 
The QuantiPro Working Reagent was prepared by mixing 25 parts of Reagent QA with 
25 parts of Reagent QB. After Reagents QA and QB had been combined, 1 part of 
Reagent QC (copper (II) sulfate) was added and mixed until it was uniform in color. 
Two chitosan solutions were prepared, one with the Aldrich commercial chitosan and 
the other one with the purified chitosan. In both cases the chitosan was dissolved in a 
0.1M HCl solution in order to obtain a 2% w/v concentration (10 mL in volume for 
each solution). The solutions are left under stirring until complete dissolution. Then the 
pH is increased with 1 mL of 1M NaOH provoking complete precipitation. Both the 
samples were centrifuged at 4500rpm for 50 minutes and supernatant collected (at this 
point the concentrations of HCl and NaOH were of both 0.09M) and analysed with a 
QuantiPro kit in a Biotek© Synergy multiplate reader: 100 µL of the supernatant or of 
albumin solutions of different concentration were added of 100 µL of QuantiPro 
Working Reagent. In the same well plate, eleven wells were filled with the standard 
protein solution; the concentrations were several in order to obtain a standard curve to 
use as a reference. The ratio of the volumes of the protein or unknown sample and 
QuantiPro Working Reagent was fixed to 1:1. The 96 well-plate was placed in 
incubation at 37°C for 2 hours, after this step the absorbance was read at 562 nm. 
The concentration of proteins in the unpurified and purified samples were measured to 
be, respectively, 19.0 µg/mL and 10.2 µg/mL, which correspond to 1.056 mg and 0.561 
mg of protein per gram of dry chitosan. 
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2.3.4 Chitosan fluorescein isothiocyanate-labeling 
100 mg of purified chitosan is dissolved in 0.10 M acetic acid solution, the pH is 
corrected to 4 with sodium hydroxide. The final volume has to be 18 mL and placed in 
a round bottom flask (capacity of 50 mL). 10 mg of FITC are dissolved in 2 mL of 
DMSO and they are slowly added to the chitosan solution using a dropping funnel. The 
final ratio of FITC respect to the D-glucosamine residue is 1:23.5. The reaction is left in 
stirring for 12 hours. Precipitation could occur at the beginning of the reaction but after 
one hour it disappears. FITC-labelled chitosan solution must be completely clear; in 
case of presence of precipitation, the pH was corrected to 3.5 using 1 N HCl. The 
solution is left under stirring for 40 min. Once had a clear solution, the volume of the 
solution is doubled with distilled water in order to reduce the risk of damage for the 
ultrafiltration membrane during the purification, this could happen due to the presence 
of DMSO. The solution is placed in the ultrafiltration chamber in order to start the 
purification with an ultrafiltration membrane of 10000 Da cut-off; solutes of high 
molecular weight are retained, while water, DMSO, non-reacted FITC and salts pass 
through the membrane. During the process, conductivity, pH and fluorescence of the 
filtrate were checked. The solution is washed extensively with distilled water until there 
is a complete absence of free FITC and absence of salts. Once the pH of the solution 
has the same value of distilled water, it is lyophilized by freeze-drying. The yield of 
reaction was evaluated; 10.5 mg of FITC-chitosan was dissolved in 49.6 mL of 0.1 M 
acetic acid solution, the fluorescence intensity was read with the luminescence 
spectrometer (λex=494 λem=518) and compared with a fitted calibration line of FITC, 
the yield of reaction was calculated to be 25.4%. 
 
2.3.5 Preparation of chitosan-TPP nanoparticles 
Chitosan was dissolved in 4.6 mM HCl at concentrations 0.038, 0.054, 0.069, 0.085 
and 0.1% wt. adjusting the pH of the different solutions to 3, 4, 4.5 or 5 by the addition 
of appropriate volumes of NaOH. All solutions were sonicated for 40 minutes. 
TPP was always prepared as a 0.1% (w/w) solution at pH = 3, 4, 4.5, 5 or 8, the pH 
value was corrected with HCl 1 N.  
Both solutions were filtered through a 0.22 µm pore size filter and, in order to remove 
any large aggregate possibly present. The complexation was then carried out at 25°C 
and under magnetic agitation (750 rpm) for a duration of 30 minutes, followed by 
   Chapter 2                                                                                        Chitosan/TPP and … 
 
39 
 
sonication for 40 minutes, leaving then the dispersion undisturbed for additional 16 
hours prior to any purification (ultrafiltration through 500 kDa molecular weight cut-off 
polyethersulphone (PES) membranes)  or analysis. Dispersions with different 
nanoparticle content could be obtained by concentrating the dispersions during 
ultrafiltration and assessing their concentration by measuring the dry content after 
freeze drying. 
Method A: variable chitosan concentration, constant volumes of solution. 
2.786 mg of a chitosan solution with concentration 0.038, 0.054, 0.069, 0.085 or 0.1% 
wt. and pH = 3, 4, 4.5 or 5 were mixed with 214 mg of a 0.1% wt. TPP solution at the 
same pH; in alternative a chitosan solution with one of the above concentrations and pH 
= 4 was mixed with a 0.1% wt. TPP solution at pH = 8. 
In the final dispersion the chitosan and TPP concentrations were therefore 0.035, 0.050, 
0.064, 0.079 or 0.093% wt. and 0.0071% wt., respectively, corresponding to 5/1, 7/1, 
9/1, 11/1 or 13/1 mass ratios between the two components. 
Method B: constant chitosan concentration, variables volumes of solution. 
A 0.1% wt. chitosan solution at pH = 3, 4, 4.5 or 5 was mixed with a 0.1% wt. TPP 
solution at the same pH, or, in alternative, the chitosan solution at pH = 4 was mixed 
with the TPP solution at pH = 8, according to the following mass ratios and for a total 
mass of 3g: 2786/214, 2750/250, 2700/300, 2625/375 and 2500/500. 
In the final dispersion the chitosan and TPP concentrations were therefore 0.083, 0.088, 
0.090, 0.092 and 0.093% wt. and 0.0071, 0.0083, 0.0100, 0.0125, 0.0167% wt., 
respectively, corresponding to 5/1, 7/1, 9/1, 11/1 or 13/1 mass ratios between the two 
components. 
Characterisation: the nanoparticles were characterised by measuring size, zeta potential 
and morphology (AFM). Due to TPP low concentration, IR analysis did not reveal any 
peak typical of phosphate groups; it is therefore generally assumed the chitosan/TPP 
ratio to be the same as in the feed. 
Preparation of fluorescent CS-TPP nanoparticles (FITC-CSNPs). 
The fluorescent nanoparticles were prepared with the FITC-labelled chitosan in the 
same fashion of the non fluorescent nanoparticles, the FITC-chitosan was used in place 
of the plain chitosan. The fluorescent nanoparticles reproduced were the type “large” 
and “small”. 
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NOTE: the breadths of both the distributions of size and that of zeta potential were 
expressed in reference to the width at half height of the distribution. When evaluating 
the dispersity in size, we have divided the width at half height of the distribution by the 
peak value, providing the aspect ratio of the distribution: in this way distributions 
peaked sometimes at largely different sizes and correspondingly present largely 
different widths half height. We have followed the same approach for multimodal 
distributions, using the size corresponding to the highest peak and the overall width of 
the distribution. 
The same approach cannot be used for the evaluation of zeta potential data, since their 
peak values are sometimes too close to zero to provide meaningful figures; therefore 
the breadth of the zeta potential distributions was evaluated just on the basis of the 
width at half height of the peaks. 
 
2.3.6 Coating of chitosan-TPP nanoparticles with hyaluronic acid 
Chitosan/TPP nanoparticles (“small” nanoparticles, method A, pH5-pH5, CS/TPP 9:1, 
Z av. size 240 nm, Zeta potential = 43.9 mV) were dispersed in a 100 mM acetic 
acid/acetate buffer at pH = 5 at a concentration of 0.05 or 0.1 wt.%. 2 mL of these 
dispersions were slowly added under vigorous stirring (30 minutes, 1200 rpm) to an 
equal amount of acetate buffer of equal strength containing hyaluronic acid of 
molecular weight 15*10
3 
g/mol and 360*10
3 
g/mol at a concentration of 0.05, 0.10, 
0.15, 0.20 or 0.50 wt.%. The dispersions were then purified via ultrafiltration using a 
500kDa cut off membrane, and concentrated up to 0.30% w/w. 
 
2.3.7 ssDNA loading tests 
Two different MW of single strand DNAs (ssDNAs) and the “small” nanoparticles 
were used for the loading tests; the concentrations of the ssDNAs used for the two 
experiments were fixed to 420 µg/mL (before loading). The ssDNA solution (35 µL, 
conc. 420 µg/mL) was added in the TPP solution (214 µL, conc. 0.1% wt.). In the same 
time a chitosan solution (2751 µL, 0.070 %wt.) was placed under stirring in a glass vial 
(10.5mL in volume). The ssDNA/TPP solution was pipetted in the chitosan solution 
and the complexation was left in stirring for 30 minutes, following the sonication for 40 
minutes. The two types of DNA were undergone in two different samples; moreover 
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two blank experiments with the two ssDNAs in TPP solution, without chitosan, were 
prepared. Three blanks of nanoparticles without the loading of ssDNAs were prepared. 
Z-average and z-potential were verified after complexation and sonication; each sample 
was precipitated with NaOH (final pH 7.4), centrifuged and filtered through a 0.22 µm 
pore size filter, and the absorbance was read with the UV/VIS spectrometer in order to 
quantify the amount of ssDNA left in the supernatant; the difference between the 
absorbance value of the supernatants and the value of absorbance in the blanks of 
ssDNA (maximum absorbance that corresponds to a concentration of 4.9 µg/mL of 
ssDNA) gives the percentage yield of loading. The purity/stability of the ssDNAs in 
each passage was confirmed by the ratio between the absorbance read at 260 nm and 
the absorbance read at 280 nm (Abs260/Abs280), this value must be between 1.3 and 2.0 
27
.  
 
2.3.8 Cell culture and cytotoxicity assays 
Murine fibroblasts L929 and macrophages J774.2 (ECACC, UK) were maintained as, 
respectively, adherent and semi-adherent cell culture at 37
o
C in humidified atmosphere 
(5% CO2) in Dulbecco modified Eagle’s minimal essential medium (DMEM, 25 mM 
glucose) supplemented with 2 mM glutamine (Gibco), 10% heat inactivated fetal calf 
serum (FCS) (Invitrogen, UK), 100 IU/ml penicillin and 100 IU/ml streptomycin 
(Gibco). For fibroblasts L929 cells splitting, trypsin-EDTA (Invitrogen, UK) consisting 
of 2.5% (w/v) of trypsin and 0.2% (w/v) EDTA in PBS was used while macrophages 
J774.2 cells were detached by scraping. For experiments, both cell lines were adjusted 
to the required concentration of viable cells, by counting in a haemocytometer in the 
presence of 0.4% trypan blue.  
The nanoparticles used for cytotoxicity experiments were purified by dialysis in PBS 
(10mM, pH 6). Once reached the equilibrium in conductivity between filtrate and PBS 
solution the samples were concentrated to the appropriate concentration in an 
ultrafiltration cell. In each step the size and z-potential was checked by DLS. 
The MTT assay measures the cell metabolic activity whereby the mitochondrial 
dehydrogenase enzyme of viable cells reduces the yellow tetrazolium salt, 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide dye (MTT), to a purple 
formazan crystals
28-30
 (Scheme 2-1).  
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Scheme 2-1. The MTT assay is a colorimetric test that measures the activity of the mitochondrial 
enzymes. The enzymes reduce the MTT in formazan, the absence of this reduction means that the 
cellular activity is diminished, either the cells are dying or they are already dead. 
 
Macrophages J774.2 and fibroblasts L929 cells were seeded in 96-well plates at 10,000 
cells per well in complete medium containing 10% FCS.  The cytotoxicity of the 
nanoparticles was evaluated using the MTT assay by determining the cells viability 
after for 24h-incubation with different concentrations of hyaluronic acid-coated or 
uncoated chitosan nanoparticles; 4h incubation was used for the tests run at 4°C and for 
their controls at 37°C, since longer incubation times at low temperature cause a drastic 
decrease in cell viability also in the absence of nanoparticles. At the end of the 
incubation period in the presence of nanoparticles, cells were washed three times with 
PBS pH 7.4 and incubated with 100 l of a MTT solution (0.5 mg/ml in DMEM) for 4 
h at 37
o
C. One hundred microliters of dimethyl sulfoxide (DMSO) were then added to 
dissolve the formazan crystals. The UV absorbance of the solubilized formazan crystals 
was measured spectrophotometrically (Microplate reader, TECAN, Safire, Austria) at 
550 nm. Cell viability was expressed as the ratio between the absorbance reading for 
cells treated with the different nanoparticles and for control non-treated cells. The 
concentration inhibiting cell viability by 50% (IC50) was obtained by interpolation of 
the cell viability curves
31, 32
. 
The LIVE/DEAD double staining kit (Sigma, St Louis, MO, USA), which allows the 
simultaneous fluorescence staining of viable (Calcein-AM, excitation 495 nm, emission 
515 nm) and dead (Propidium iodide, PI, excitation: 535 nm, emission: 617 nm) cells
33, 
34
, was used. Macrophages J774.2 were seeded in a 96-well plate at a count 8,000 
cells/well and incubated for 24h with 0.1 mg/ml of coated or uncoated chitosan/TPP 
nanoparticles (CSNPs). After removal of the two treatments, cells were washed with 
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PBS, incubated with solution of both stains for 15 min at 37
o
C and then observed under 
fluorescent microscope (Leica DMI5000,) at 20-fold magnification. Both Calcein-AM 
and PI-DNA were excited with 490 nm, allowing simultaneous monitoring of viable 
and dead cells while with 545 nm excitation, only dead cells were observed. In order to 
quantitatively assess the data obtained from the fluorescent images, the total number of 
cells and number of dead cells in 3 microscopic fields were counted (ImageJ 1.4d, 
USA) such that each microscopic filed contains around 300-360 cells.  Each NPs 
formulation was assayed at least in triplicate wells. 
All experimental results are expressed as mean ± SD. Statistical tests of significance 
were performed using one-way ANOVA followed by Bonferroni test for multiple 
comparisons at P < 0.05 (Origin® 7SR1, Northampton MA, USA). 
 
2.3.9 Cellular Uptake of FITC-CSNPs and FITC-HA-CSNPs 
Cellular Uptake of CSNPs and HA-coated CSNPs by Microscopy techniques. 
Macrophages J774.2 and Fibroblasts L929 cells were grown on cover slips, FITC-
CSNPs or FITC-HA-CSNPs were suspended in DMEM (serum-free medium) or PBS. 
The cells were incubated separately with HA-coated and uncoated nanoparticles for 30 
minutes at 37°C. Extracellular fluorescence was quenched with a trypan blue solution
35
. 
The cells were washed with PBS, followed by the fixation with 4% methanol-free 
formaldehyde and permeabilization with 0.1% Triton-X100. The Texas Red Phalloidin 
(TxR-phalloidin, Exmax/Emmax 591/608 nm) was used to label the actin filaments, the 
4',6-diamidino-2-phenylindole (DAPI, Absmax/Emmax 358/461 nm
36
) was used to label 
the nucleus. The problem of overlapping in the emission of fluorescence between the 
DAPI, TxR-phalloidin and FITC is avoided taking images of the same cells 
sequentially. The confocal or fluorescent microscopes were used for taking the images. 
Cellular uptake of HA-coated and uncoated CSNPs by Micro-fluorimetric Assay.  
Macrophages J774.2 cells were seeded in black 96-well plate-transparent bottom. The 
HA-coated and uncoated nanoparticles were placed in incubation with the cells 
subjected to different variables like nanoparticles concentrations, incubation times and 
presence of several effectors. At the end of the incubation period, the cells were washed 
with a PBS solution and then the lysis of the cells was performed with 0.5% Triton-X 
100 in 0.2 N NaOH. The quantitation of nanoparticles uptake was expressed as 
micrograms of nanoparticles internalized divided milligrams of cellular proteins. 
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Calibration curve was plotted in order to relate the amount of nanoparticles with the 
fluorescence intensity (RFU), the fluorescence intensity was measured with a 
microplate reader (TECAN, Safire, Austria); the protein content was quantified with the 
QuantiPro Micro BCA assay kit. 
 
2.4 Results and discussion 
2.4.1 Preamble 
In this study we have used chitosan with high degree of deacetylation (≈90%), 
employing a precipitation-redissolution procedure for removing contaminants, which 
are supposedly, but not necessarily, of proteic nature. The process did not modify the 
degree of deacetylation, which was evaluated through 
1
H-NMR, IR and colloid 
titration, nor the intrinsic viscosity of the polymer, but removed a significant amount of 
contaminants in form of soluble proteins or colloidal impurities, which are capable of 
significantly affect both the process of nanoparticle formation and the interactions with 
cells.  
As a qualitative measure of the efficacy of the purification procedure, the amount of 
base-soluble proteins is reduced to about 0.05 wt. % of the chitosan mass (roughly 50% 
of the initial base-soluble protein content): this would correspond to a protein content of 
0.5 ppm for a 0.1% chitosan concentration, a protein level that was deemed acceptable 
for further use. 
 
2.4.2 Preparation of chitosan/TPP nanoparticles 
Variables and observables. We have investigated the influence of chitosan/TPP mass 
ratio, of pH and of the mixing procedure on the phenomenon of nanoparticle formation, 
monitoring the effects of these variables on the average value and the dispersity of size 
and zeta potential, and on the stability of these values and of pH at two different time 
points: 16 hours after complexation and then 30 days, in order to highlight possible 
stability issues. 
- Since an excess of chitosan has always been used, the chitosan/TPP mass ratio is 
inversely related to the cross-link density of the material; larger ratios therefore 
correspond to lower cross-linking densities and thus to softer materials, but also 
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possibly to a slower kinetics of formation (both nucleation and growth), which may 
mean a more “thermodynamically” controlled process of formation. Specifically, we 
have varied the mass ratio between 5:1 and 13:1. 
- The environmental pH can be varied only within a restricted range, since very acidic 
pH will lower the charge of TPP, decreasing its cross-linking capability, while pH 
larger than 6 would lower the charge density of chitosan, decreasing not only its 
capability to be cross-linked, but also its solubility, promoting its self-association. We 
have therefore performed most complexation experiments mixing TPP and chitosan 
solutions with an identical pH, with values ranging between 3 and 5. Additionally, we 
have explored an alternative procedure by mixing an acidic (pH = 4) chitosan solution 
in combination with a slightly basic (pH = 8) TPP solution. The transient exposure of 
chitosan to region of higher pH may induce some aggregation, increasing its local 
concentration: this may increase the number of nuclei available for nanoparticle growth 
(higher nucleation rate → smaller particles) larger nanoparticles, but it is also possible 
the aggregates to cluster in a TPP-mediated fashion (hence larger particles). 
- We have mixed chitosan and TPP solutions according to two different methods: A) 
constant volume ratio between the two solutions, but different concentrations. Since all 
solutions are very dilute, we do not expect them to significantly differ in viscosity; 
therefore the mixing dynamics should be substantially identical for all samples. Any 
difference recorded in the nanoparticle properties should be ascribed simply on the 
thermodynamic and kinetic features of the complexation process. B) Solutions with 
constant concentrations of TPP and chitosan (0.1% for both), but mixed in different 
volume ratios. Differences between the results of this set of experiments and those of 
method A would signal that the fluidodynamics of mixing of the two solutions and/or 
local concentration of the polyelectrolytes have important effects on nanoparticle 
formation. 
Effects on nanoparticles properties. The graphs in Figure 2-2 and 2-3 three-
dimensionally show the influence of the above variables on the average size of 
chitosan/TPP nanoparticles (the darker the colour, the smaller the nanoparticle size) and 
on the aspect ratio of their size distribution (the larger the circles, the more 
“monodisperse” the distribution), or on the zeta potential (the darker, the more positive) 
and of the width at half height (again, the larger the circles, the narrower the 
distribution). Only experiments with a reliable scattering intensity were reported, thus 
excluding all the combinations that provided soluble, very small or extremely 
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polydisperse materials; therefore, when at a certain time point an experimental point is 
not reported, the values at the same position in different graphs must be taken as purely 
indicative, due to the impossibility of a quantitative comparison. Figure 2-4 presents the 
pH variation of the dispersions between the two time points of 16 hours and 30 days. 
The following considerations apply: 
- it is apparent that method B generally provides largely different results from method 
A, showing that the nature of the mixing process has a profound influence on the 
nanoparticle properties. Additionally, a number of samples prepared through method B 
at one or the other time point are not analysable (too low scattering intensity and/or too 
large polydispersity). 
- the use of two solutions with different pH has a marked effect and leads to 
significantly larger nanoparticles. Firstly, this indicates that a higher pH in the TPP 
solution induces some form of chitosan aggregation: if not, no effect would be 
recorded. The final nanoparticles, however, are not simply formed by chitosan 
aggregates, because they would re-dissolve at the equilibrium pH (5.5-6); therefore, 
these nanoparticles are likely to be formed through the association of chitosan clusters. 
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Figure 2-2. Average size and aspect ratio of the size distributions (average over three different 
preparations) as a function of chitosan/TPP mass ratio and pH of both solutions, using two mixing 
methods and recorded at two different times. For an easier reading, the pH values are highlighted with 
black crosses at the bottom of graphs. In some positions symbols are absent, due to very low values of 
the scattered intensity of the corresponding samples. A representative size distribution curve is shown in 
Figure 2-27. 
 
- the use of solutions at pH = 3, on the contrary, generally provides very low amounts 
of nanoparticles, close to the detection limit of dynamic light scattering. This is likely 
due to the decreasing charge density of TPP with decreasing pH (TPP’s pKa3 = 2.3, 
therefore at pH =3 slightly less than 20% of its molecules are only double charged). A 
very high chitosan/TPP ratio seems a detrimental factor too (low cross-linking density),  
- particles evolve with time, in some cases their size increases (aggregation), but more 
frequently it decreases; in general, the variation is more pronounced for particles 
obtained through method B than for method A. We are inclined to ascribe this effect to 
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the formation of a more compact matrix, i.e. new cross-links could be formed, releasing 
couples of counterions, and the slow kinetics is likely due to the fact that this process 
happens in an already cross-linked matrix. We expect a tighter complexation with 
chitosan and TPP to increase the basicity of amines: TPP is not a mobile counterion and 
has a multiple charge; therefore it can shield the positive charge of a protonated amine 
more effectively than e.g. a chloride or an acetate. Hence a neighbouring amine can be 
easier deprotonated due to the lower electrostatic repulsion; correspondingly we assume 
that a sound increase in cross-linking density may lead to an increase in pH. The pH of 
the particles obtained through method A is substantially stable, with a slight acid drift 
for those with higher size stability, while a clear increase up to one pH unit is seen for 
method B particles, which would confirm the possibility of a slow-running 
complexation.  
 
 
Figure 2-3. Average Zeta potential and width at half height for the Zeta potential distribution (average 
over three different preparations) as a function of chitosan/TPP mass ratio and pH of both solutions, 
using two mixing methods and recorded at two different times. For an easier reading, the pH values are 
highlighted with black crosses at the bottom of graphs. Where brackets are used, the samples showed 
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very low scattered intensity in DLS analysis and the values of Zeta potential have to be considered just 
qualitative. A representative Zeta potential distribution curve is shown in Figure 2-27. 
 
- The average Zeta potential of all samples is largely positive, with reasonably narrow 
distributions fully comprised within the positive potential region. These data do not 
appear to have any dependence on the studied variables for method B particles; for 
method A particles it seems lower pH samples to show the broadest dispersity 
immediately after preparation and the narrowest after ageing; the variability of these 
data is, however, fairly large and it is difficult to conclusively ascribe this effect to a 
specific phenomenon. It is noteworthy that within the pH range used for the production 
of stable particles (between 4 and 6), the Zeta potential did not show any sound 
dependence on pH. 
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Figure 2-4. pH stability of the dispersions presented in Figures 2-2 and 2-3, expressed as the difference 
between the pH values at 16 hours and 30 days. 
 
Selection of optimised nanoparticles. For further investigations we have selected two 
kinds of nanoparticles, which show the best combination of stability of size, Zeta 
potential and pH, high value of the average Zeta potential and narrow size dispersity, 
and are characterized by a “small” (200-300 nm in deionised water) or a “large” (300-
400 nm) size. Our aim is to employ the “small” nanoparticles for further coating with 
hyaluronic acid: this process is very likely not only to modify their surface, but also to 
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increase their size; therefore we have chosen to target also “large” nanoparticles as a 
reference system that will exhibit similar size and bulk composition to the coated ones. 
The above features could be obtained by using method A, moderate chitosan/TPP ratios 
and pH = 4.5-5 for a lower average size, and pH = 4 and 8 for a larger size. 
Specifically, the following conditions were chosen:  
“small” nanoparticles, pH5 for both solutions, chitosan/TPP 9:1, Z-average size 240 
nm, Zeta potential =  43.9 mV. 
“large” nanoparticles, pH4-pH8, CS/TPP 13:1, Z-average size 360 nm, Zeta potential = 
47.0 mV 
 
2.4.3 Environmental effects on chitosan/TPP nanoparticles 
Chitosan/TPP nanoparticles are kept together by electrostatic forces, which clearly 
depend on the protonation extent and on the concentration of the ionic species.  
Effect of pH. As suggested by the nanoparticle formation experiments conducted using 
pH = 3 solutions, an acidic environment is detrimental for the nanoparticle stability, 
because the protonation of TPP lowers its charge. Chitosan neutralization should set the 
upper stability limit. Indeed it can be seen (Figure 2-5) that under acidic conditions, at 
pH = 3 the scattering intensity is already low enough to hardly allow a reliable zeta 
potential determination and below it drops further. It is worth mentioning that DLS 
does not show any variation in dimensions (swelling), but just a decrease in the number 
of scattering particles. At pH > 6, on the other hand, the Zeta potential approaches 
neutrality and, instead of dissolution, the nanoparticles undergo agglomeration and 
macroscopic flocculation. 
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Figure 2-5. Dependence of the z-average size and of the Zeta potential on the pH for the “large” 
nanoparticles. A similar trend is recorded for the “small” nanoparticles. It is worth mentioning that the 
data were obtained by adding appropriate quantities of HCl or NaOH to the nanoparticles originally at 
pH = 5.5, without the use of any buffer. 
 
Presence of ionic species. Due to the existence of a “stability window” in the pH 
region between 4 and 6, the use of buffers for the long-term storage of the dispersions 
appears to be the most logical solution. Since, however, the nanoparticles are held 
together and stabilised by electrostatic forces, it is of the essence to understand whether 
the presence of ionic species may influence their morphology and/or stability. Indeed 
upon exposure to moderate or high ionic strength buffers, the nanoparticles show a 
sound reduction in size to 62-68% the original average diameter, corresponding to a 
shrinkage to roughly one third of the initial volume. The extent of the shrinkage was 
substantially analogous in 10 mM PBS at pH = 6 (Figure 2-6) and in 100 mM acetate at 
pH = 5, with a negligible influence on the Zeta potential in both cases. 
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Figure 2-6. Changes in the size distribution of “small” and “large” chitosan/TPP nanoparticles as a 
consequence of the exchange of the medium from deionised water to 10 mM PBS. 
 
2.4.4 Hyaluronic acid-coated nanoparticles 
Due to the surface charge reversal, the adsorption of a polyanion on positively charged 
nanoparticles can result in agglomeration and possibly flocculation, either because of 
the interactions between positively and negatively charged patches on different 
nanoparticles, or because of the absence of electrostatic stabilization during the 
intermediate states of the adsorption.  
The final outcome, i.e. surface functionalisation vs. agglomeration, depends on 
concentration and size of both nanoparticles and polyanion and on the strength of their 
interactions. Since the last parameter is automatically set by the choice of the materials 
(interactions between protonated amines and carboxylates) and pH (5 to ensure both 
stability of the initial chitosan nanoparticles and sufficient deprotonation to HA), we 
have studied the influence of the other parameters, limiting our investigation to dilute 
systems, in order to minimize the chance of aggregation, to “small” nanoparticles and 
to two HA molecular weights (15*10
3 
g/mol and 360*10
3 
g/mol).  
We have coated only “small” nanoparticles because the deposition of HA is likely to 
increase their size up to a few tens of nanometers: therefore coated “small” 
nanoparticles are likely to be analogous in size and bulk composition to the uncoated 
“large” nanoparticles, which therefore would be an ideal reference system to highlight 
effects arising only from surface composition. On the other hand, no similar reference 
system would be available for the coated “large” nanoparticles.  
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Very high molecular weight HA was excluded, on the grounds that the high viscosity of 
its solutions could result in scarcely reproducible experiments. 
Our experiments have shown that a low molecular weight of HA, on the other hand, 
appeared to be detrimental to the stability of the nanoparticles (Figure 2-7). Low 
polydispersity and reasonably low size increase was on the contrary recorded with HA 
of MW=360*10
3 
g/mol at concentrations comprised between 0.1 and 0.2 wt.%. 
The lowest polydispersity and the smallest size increase (average size = 260 nm in 
acetate buffer, compared to 160 nm before adsorption) were recorded for the 
combination of “small” nanoparticles at 0.05 wt.% and HA at 0.15 wt.%. These 
conditions suggest a very moderate agglomeration, with the volume of a final particle 
corresponding to that of 3-4 parent ones, and were therefore adopted for any further 
investigation. 
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Figure 2-7. Average size and aspect ratio of the size distributions (top), average Zeta potential and width 
at half height for the Zeta potential distribution (bottom) as a function of nanoparticle and HA 
concentration. For an easier reading, the concentration values are highlighted with black crosses at the 
bottom of graphs 
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A morphological comparison of the three different kinds of nanoparticles through 
Atomic Force Microscopy (Figure 2-8) highlights a few important points: 
- the dimensional difference between “large”, “small” and HA- nanoparticles is real and 
not an artifact of the DLS analysis. It is noteworthy that the HA-coated nanoparticles, 
although each likely obtained through the agglomeration of few “small” ones, do not 
appear as clusters.  
- all nanoparticles are soft and flatten when deposited on a solid surface. This is likely 
due to the low cross-link density.  
- “Large” and HA-coated nanoparticles generally show some fracture lines as a 
consequence of drying, which suggests them to display a harder surface. “Small” 
nanoparticles appear to be always surrounded by a halo, which is barely visible in 
height images but more clear in phase images (not shown), indicating it to be very soft 
and thin; we interpret it as a “fuzzy” corona composed by tethered chitosan chains. 
Consistently with this hypothesis, the halo disappears after coating,  
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Figure 2-8. AFM analysis of the three different kinds of nanoparticles deposited on mica surfaces from 
dispersions in deionised water. The lower (left) or higher (centre) magnification pictures and the height 
scans along the median point of particles (right) highlight the larger dimensions of “large” and HA-
coated nanoparticles compared to the “small” ones.  
 
2.4.5 ssDNA loading tests 
The nanoparticles with embedded ssDNAs did not show significant difference in sizes 
and zeta potentials compared with the blanks of plain nanoparticles (Table 2-2). 
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Table 2-2. DLS measurements, 1A = nanoparticles with ssDNA (MW = 5569 g/mol), 1B = nanoparticles 
with ssDNA (MW = 16004 g/mol), 1C1 = 1C2 = 1C3 = plain nanoparticles without ssDNA. 
 
 
 
The Figure 2-9 shows the UV/VIS spectra of the nanoparticles supernatants and of the 
ssDNAs blanks. There is no presence of absorbance of ssDNAs in the range of 
wavelength 240-290 nm in the supernatant of the sample of nanoparticles 1A and 1B, 
this imply that all the DNA, complexed with the chitosan nanoparticles, was removed 
with the precipitation of the nanoparticles; therefore it is presumed the 100% of 
loading. Furthermore, it was notice, from the spectra of the DNA blanks, a decrease in 
purity/integrity of the fragments after 24 hours of storage, especially in the ones that 
were besides sonicated; the major damage was in the fragments with high MW. 
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Figure 2-9.  UV/VIS spectra (from the top to the bottom of the legend): “a” is the ssDNA spectra with 
MW 5569 g/mol in TPP solution at time 0; “b” is the ssDNA spectra with MW 16004 g/mol in TPP 
solution at time 0; “c” is the spectra of “a” sonicated for 40 minutes at time 0 and then checked after 24h; 
“d” is the spectra of “b” sonicated for 40 minutes at time 0 and then checked after 24h; “e” is the spectra 
of “a” after 24h; “f” is the spectra of “b” after 24h; “g” is the supernatant spectra of the sample 1A 
against 1C (blank without ssDNA); “h” is the supernatant spectra of the sample 1B against 1C (blank 
without ssDNA); “i” is the supernatant spectra of the sample 1C against double distilled water. 
The numbers that are after the name in the legend (lines “a” to “f”), identify the grade of purity of the 
single strand DNAs (the value Abs260/Abs280 must be in the range 1.3-1.5, however varying pH and ionic 
strength this value can increase till 2.0)
27
.  
 
In the future, a more reliable quantitation of DNA or RNA concentrations will be the 
use of fluorescent tags bound with the nucleic acids, and proceed with the detection of 
the fluorescence intensity; this method is much more accurate and cases of 
contaminants absorbing in the range 240-280 nm are efficiently avoided. The use of 
nuclease-free water during the experiments decreases the damage of DNA or RNA by 
the activity of the free nucleases in the environment. 
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2.4.6 Evaluation of nanoparticle cytotoxicity  
Cytotoxicity was evaluated on two murine cell lines: J774 macrophages as a model for 
professional phagocytes
37-39
 and L929 fibroblasts as a non-phagocytic and widely 
recommended reference cell line
40, 41
. Two methods were employed: the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay to evaluate the effects 
that nanoparticles may have intracellularly on mitochondria and metabolic activity and 
determine IC50 values for the above nanoparticles, and a Live/Dead fluorimetric assay 
(calcein/propidium bromide) to assess not only cell death,  but also possible non-lethal 
cell membrane damage, since the first site of interaction of nanoparticles is likely to be 
the cell membrane
31, 42
. The combination of these two different methods can provide 
hints about the modus operandi of the nanoparticle toxicity, since effects may appear at 
lower concentrations or shorter times than those recorded through the measurement of 
mitochondrial activity. 
The results of the MTT assay (Figure 2-10) clearly show that 
- for all nanoparticles and at any concentration, cytotoxicity was always higher for 
macrophages than for fibroblasts. Specifically, the decrease in viability recorded on 
fibroblasts is still small also at concentrations as high as to 2 mg/ml.  
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Figure 2-10. Cell viability (MTT assay) for L929 fibroblasts and J774 macrophages as a function of 
nanoparticle concentration at 37
o
C after 24 h exposure. Provided by Dr Noha Zaki. 
 
- Using macrophages as a more sensitive model, it is also apparent that the uncoated, 
positively charged nanoparticles have higher cytotoxicity than the HA-coated ones. 
“Large” and “small” nanoparticles show IC50 values in between 0.7 - 1.0 mg/ml; 
although “small” nanoparticles often show higher cell viability than the “large” ones, 
the data offer no statistically significant difference. The HA-coated nanoparticles show 
a higher IC50 of about 1.8 mg/ml.  
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Figure 2-11. Fluorescence microscopy pictures (overlaid) of metabolically active (green) and membrane-
damaged (red) cells. It is apparent that while pure culture media and 0.1 mg/mL HA-coated nanoparticles 
show both negligible toxic effects, a 0.1 mg/mL dispersion of the uncoated and positively charged 
“large” nanoparticles has a detrimental effect on the cell viability; interestingly, there is large number of 
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cells with reduced green fluorescence, but substantially no overlap between red and green-emitting cells. 
Provided by Dr Noha Zaki. 
 
- The more benign character of the HA-coated nanoparticles is also revealed by the 
Live/Dead assay at concentrations where the MTT assay still indicates no significant 
decrease of viability (0.1 mg/mL). “Large” nanoparticles have a fraction of membrane-
damaged cells which is considerably higher than for the HA-coated ones, which on its 
turn is almost undistinguishable from the control (Figure 2-11). It is noteworthy those 
red and green emissions are not co-localised and that there are a considerable number 
of cells with low green emission, but no red one. This is likely an indication that 
membrane damage, i.e. penetration of the red-emitting propidium iodide in the cell, 
takes place only after a sound decrease of the cell metabolic activity. Therefore, even 
when the nanoparticles are positively charged, they appear to have a toxic effect 
directly on metabolism rather than on membrane properties; a logical conclusion is that 
their cytotoxicity is mediated by their intracellular uptake, a finding corroborated by 
several literature reports
43, 44
. 
- The higher sensitivity of macrophages could therefore be due to their higher 
internalisation activity. This hypothesis is confirmed by conducting the experiments at 
4
o
C, i.e. at a temperature where active endocytosis is substantially inhibited (Figure 2-
12): the decrease in temperature increased the viability of macrophages at surely 
cytotoxic concentrations at 37
o
C.  
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Figure 2-12. Comparison of the viability (MTT assay) of J774.2 macrophages after 4h exposure to 
uncoated chitosan/TPP nanoparticles at 4 (blue bars) and 37
o
C (red bars). It is apparent that, above all at 
   Chapter 2                                                                                        Chitosan/TPP and … 
 
64 
 
higher nanoparticle concentrations, toxic effects disappear at low temperature. Chitosan nanoparticles 
concentration were 1.8 mg/ml and 0.18 mg/ml (mean±sd, n=8)). Provided by Dr Noha Zaki. 
 
Our data therefore suggest that the cytotoxicity of chitosan nanoparticles appears to be 
mostly dependent on their internalisation, which on its turn seems to be scarcely 
dependent on size and clearly dominated by surface composition/charge: indeed it is 
well known that positively charged nanoparticles are more quickly internalised than 
negatively charged ones, possibly utilising clathrin-mediated mechanisms
45
, where, 
however, interactions with membrane-linked negatively charged GAGs may play a role 
too
46
. 
 
2.4.7 Nanoparticles uptake 
The uptake was evaluated using Macrophages J774.2 and Fibroblasts L929 cells for 
both uncoated CSNPs and HA-coated CSNPs. Two methods were employed: the use of 
microscopy techniques by using confocal or fluorescent microscope and have 
qualitative data, and the micro-fluorimetric assay to obtain quantitative data.  
Chitosan nanoparticles uptake. The cells were incubated with the nanoparticles for 
30 minutes, and after several washings, the trypan blue was used to quench the signal of 
fluorescence outside the cellular membrane
35
. This was performed in order to 
distinguish between CS-NPs internalized and those adhering to the cellular membrane. 
The localization of CSNPs appears to be mainly in the cytoplasm (Fig. 2-13), this 
means that there is a potential for cytosolic delivery. 
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Figure 2-13. Localization of CS-NPs in the Macrophages J774.2. Images of the same cells taken 
sequentially with different value of excitations: on the top left the actin staining, on the top right the 
fluorescent nanoparticles, on the bottom left the nucleus staining and on the bottom right the overlay of 
all the three images. Provided by Dr Noha Zaki. 
 
 
 
Figure 2-14. Effect of Bafilomycin A1. The Bafilomycin A1 is an inhibitor of vacuolar ATPase 
endosomal proton pumps and inhibits the acidification of vacuoles. The use of this inhibitor highlights 
the co-localization of the CSNPs in the endosomes and in the lysosomes preventing their endo-lysosomal 
escape. Provided by Dr Noha Zaki. 
 
CS-NPs were internalized by Macrophages J774.2 in an energy-dependent endocytic 
process. This was indeed demonstrated when the cells, under effect of energy depletion 
by sodium azide or treated at a lower temperature, showed a diminution in uptake (Fig 
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2-15), and more exactly the decrease in internalization went down to 58% and 70% 
respect to the cells control.  
 
 
 
Figure 2-15. Effect of metabolic inhibitors on CS-NPs uptake by Macrophages J774.2. Provided by Dr 
Noha Zaki. 
 
The mechanism of CSNPs uptake by Macrophages J774.2 was highlighted with a test 
that use several endocytosis effectors, objective is to discover, by exclusion, which 
system rules the internalization. The results were the followings (Fig. 2-16): the 
inhibition of endocytosis by caveola-coated pit by using filipin did not affect soundly 
the CSNPs uptake (+27% in comparison with the control); as well the use of 
Bafilomycin A1, a specific inhibitor of proton pumps in the endosomes, did not alter 
deeply the degree of internalization (+20%). Nocodazole and Cytochalasin D, 
respectively inhibitors of microtubules formation and of actin polymerization, slightly 
affect the internalization (-25% and -26%); moreover, a K
+ 
free buffer imply a 
diminution in cellular excitability with a decrease in nanoparticles uptake (-26%). Only 
the hypertonic growth medium reduces the cellular uptake drastically (-47%), 
consequently, it is evinced that the activity of the clathrin-coated pit has a central role 
in the CSNPs internalization. 
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Figure 2-16. The uptake of uncoated CSNPs by Macrophages J774.2 was tested under different 
endocytosis effectors. Provided by Dr Noha Zaki. 
 
HA-coated chitosan nanoparticles. The cells were incubated with the nanoparticles 
for 30 minutes, after the washings there was non need of trypan blue since the HA-
CSNPs did not interact so strongly with the cellular membranes like the uncoated ones 
did. The images at the microscopes confirmed the localization of the nanoparticles in 
the cytoplasm (Fig. 2-17). The kinetic of HA-CSNPs uptake was evaluated taking 
images of Macrophages J774.2 cells in incubation at different time, it was observed that 
the HA-CSNPs uptake starts after 2 hours of incubation and appear to be biphasic (Fig. 
2-18, 2-19, 2-20).  
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Figure 2-17. Localization of HA-coated CS-NPs in the Macrophages J774.2. Images of the same cells 
taken sequentially: on the top left the actin staining, on the top right the fluorescent nanoparticles, on the 
bottom left the nucleus staining and on the bottom right the overlay of all the three images. Provided by 
Dr Noha Zaki. 
 
 
Figure 2-18. Time course of HA-coated CSNPs uptake (0.05mg/ml) by Macrophages J774.2 at 37°C. 
The HA-NPs were taken up after a lag period of 2h incubation. The type of uptake is biphasic. Provided 
by Dr Noha Zaki. 
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Figure 2-19. Kinetic of internalization of HA-coated CS-NPs in Macrophages J774.2. Provided by Dr 
Noha Zaki. 
 
The mechanism of HA-CSNPs internalization was clarified, different endocytosis 
effectors were used for this purpose, thus to discover also in this case, like with the 
uncoated nanoparticles, which is the system that regulates the internalization (Fig. 2-
21). The results showed that: the inhibition of microtubules formation by Nocodazole 
provoked a higher increase in nanoparticles uptake (+48%). The use a Filipin and 
Cytochalasin D did not bring sound differences (+5% and -24%), the caveola-coated 
pits were not involved and the blockage of actin polymerization did not hinder greatly 
the internalization. 
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Figure 2-20. Effects in the uptake of HA-coated NPs. The sampling was performed at different 
concentrations and different time of incubation. The cellular uptake is carried out by Macrophages J774.2 
at 37°C. It is noted that the uptake is time and concentration dependent; the differences in terms of 
concentration were highlighted after 6 hours of incubation. Provided by Dr Noha Zaki. 
 
There was a strong decrease in the internalization (-41%) in the cells treated with 
Bafilomycin A1, the HA-coated nanoparticles had much difficulties in the escaping 
from the endosomes with the blockage of the proton pumps, the buffer effect of the 
nanoparticles was not implying the break out of the in the cytosol; possibly the low 
internalization it was justified because of the endosomes recycling and so the excretion 
of the nanoparticles from the cells. Similar to the uptake mechanism of the uncoated 
CSNPs, the main decrease in uptake (-46%), for the HA-coated nanoparticles, was due 
to the higher concentration of sucrose, the endocytosis is clathrin-dependent in this case 
too. 
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Figure 2-21. The uptake of HA-coated CSNPs by Macrophages J774.2 was tested under different 
endocytosis effectors. Provided by Dr Noha Zaki. 
 
2.5 Conclusions 
As a result of the application of a robust approach for the optimization of the method 
for the chitosan/TPP nanoparticle preparation, we have focused on “small” 
nanoparticles with a size ≤200 nm, which were later coated with hyaluronic acid (HA), 
and on “large” nanoparticles with a size 200-400 nm, which can be used as a control for 
the HA-coated ones, featuring analogous dimensions but different surface properties. 
The HA-coating markedly reduces the nanoparticle toxicity and increases the colloidal 
stability; the internalization of the HA-coated CSNPs is delayed respect to the uncoated 
ones (no cellular uptake before 2 hours),  it is important to note that the lower 
cytotoxicity due to polysaccharidic coatings, demonstrated in the past for a number of 
nano-carriers, e.g. also dextran-coated nanoparticles
47
, often corresponds to longer 
circulation times in vivo
48, 49
. 
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2.6 Supporting information 
 
Figure 2-22. The IR spectra of chitosan before and after purification show a substantial overlap. 
 
 
 
Figure 2-23. 
1
H-NMR of chitosan (Aldrich) in 0.5 M DCl/D2O before purification, %DD = 91.01% 
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Figure 2-24. 
1
H-NMR of purified chitosan in 0.5 M DCl/D2O before purification, %DD = 92.02 % 
 
 
Figure 2-25. Standard curve for the protein determination assay. 
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Figure 2-26. FITC calibration line. The dilutions were executed with 0.1M acetic acid. 
 
Figure 2-27. Size and Zeta potential distributions for “small” nanoparticles. 
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Table 2-3. Live/dead results for macrophages J77.4 cells  
 Control HA-coated NPs “large” uncoated NPs 
No. of damaged cells 10±4 13±5 48±6 
Total No. of cells 342±12 330±11 320±14 
Damaged cell fraction 0.036± 0.003 0.045±0.005 0.14±0.02** 
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3 Chitosan/TPP microparticles 
3.1 Summary 
The production of chitosan-based matrixes, or microparticles by ionotropic gelation 
with sodium triphosphate was abundantly studied
1-3
; the need for an efficient 
production of monodisperse micro-beads in a sterile condition, the possibility to have 
high percentage of loading without waste and the opportunity to scale up the production 
without use large amount of materials, makes of the Inotech® encapsulator one of the 
best device for the entrapment of biomolecules, cells, proteins and others actives for 
medical, cosmetic, agricultural or food purposes.  
This work was focused on the use of this device combined with the ionotropic 
gelation technique, thereby the use of chitosan and its counterpart sodium triphosphate. 
Chemical parameters and instrumental constraints were optimized in order to obtain the 
best kinetic of complexation and the best physical conditions for the production of the 
microparticles. Solely one group
4
 worked on the production of chitosan-based 
microparticles using the Inotech encapsulator, and however they fabricate these by 
simple precipitation without the use of complexant agent like sodium triphosphate. It is 
for this reason that is important to focus on the potentiality of chitosan in the 
immobilization of actives principles and investigate the main properties of the beads. 
 
3.2 Introduction 
The preference of a material for the microparticles formation is determined 
depending on the purposes. In medical application, the low toxicity of a substance is the 
most important parameter followed by the efficiency in the mechanical properties. 
Concerning the delivery of an active principle, the transport capacity and the shape are 
factors to optimize. 
In the last twenty five years the production of chitosan-based microparticles has 
been a target in many fields, from the treatment and purification of the water waste to 
the food and medical applications. Focusing on this last function, the production of non 
toxic beads can be exploited and optimised for intestinal or topical drug delivery, these 
should have a satisfactory mechanical properties and an efficient loading and controlled 
release. A zero order release is the optimal trend for pharmacokinetics purposes, indeed 
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a constant concentration, compared to a sudden rise or fall of actives in the blood or in 
the tissues, is preferable in order to avoid side effects. 
Factors influencing the diffusion of a solute in a polymer matrix are various: chain 
mobility, degree of entanglement, crosslinking density, degree of swelling, crystallinity, 
porosity, and interaction between the solutes and the matrix
5
. The diffusion depends on 
the solute size, on the mesh created by the polymer chains and the relaxational 
behaviour of the network. Modulating the degree of crosslinking of a polymer matrix, 
the release of an active principle with a fixed molecular size can be regulated. 
 
 
Figure 3-1.  An example of crosslinked polymeric matrix; the circles are “blobs”, a term coined by de 
Gennes
6
, it is a concept used to explain the free movement of chain segment. The mesh size  
ξ is the empty parts not overlapped by the blobs (inspired by de Gennes et al 6). 
 
3.2.1 Chitosan-TPP microparticles 
The chitosan can be used for microparticles production, the use of the biopolymer 
gives the prospect to modulate the pore size, the diffusional, the loading properties and 
the degree of swelling of the beads varying the concentrations, pH, ionic strength and 
dissolution medium
2, 7
. It is also known that the intermolecular linkages are in larger 
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numbers with the increase in molecular weight but the shrinking and the porosity of the 
microparticles depend deeply on the method of drying
2
. Moreover, the degree of 
linkages influences the release and diffusion of molecules
8
 and the degree of hydration 
of the matrixes
5
. The diffusion of molecules, the ones that do not have interactions with 
the matrix network, is ruled by the Fick’s law9, 10; the flux of molecules goes from a 
more concentrated area to a less concentrated, the magnitude is proportional to the 
concentration gradient: 
            (I); 
where J is the diffusion flux, D is the diffusion coefficient, φ is the concentration in 
moles/m
3
 and x is the position of the molecules. 
 
3.2.2 Techniques of production of microparticles 
The production of microparticles chitosan-based can be processed by using several 
techniques: 
- physical gelation. Molecules or polymer with opposite charges simply complex 
by ionotropic forces, the most used polyanions were sodium triphosphate (TPP)
11
, 
alginate
12
, pectin
13
 and similar molecules; 
- complex coacervation consists in the preparation of a solution with three 
immiscible phases, one with the core material, a coating material and a solvent.  
The coating will deposit around the core material in the moment when a change of 
parameter happen, that could be temperature, pH or ionic strength
14-16
; 
- spray drying is a technique which allow the production of dry powders or 
agglomerates from raw excipients and drugs in form of suspensions or solutions; 
this technique need the presence of a crosslinking agent like glutaraldehyde or 
formaldehyde
17
; 
- emulsification/solvent evaporation is a method that use a double emulsion in 
order to maintain monodisperse the particles and work at the same time with 
hydrophobic polymers
18
. 
The first two methods provide extremely mild and safe conditions; physical gelation is 
the chosen method to be used with the available equipment, the Inotech® encapsulator. 
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3.2.3 Jet break-up technology 
The encapsulator IE-50 R can be used for the biopolymer encapsulation of 
microbial, animal, plant cells or other pharmaceuticals and biomolecules. The vibration 
technology is a powerful tool to obtain reproducible control of bead formation, sterile 
conditions of application and possibility to scale-up in production lines
19
. The bead 
formation technique is possible since a laminar liquid flow can be broken in uniform 
droplets and gelify in beads once they are in a hardening bath. 
The instability of liquid jets was initially studied by Rayleigh
20
; he demonstrates that 
the frequency for the production of stable droplets was related with the jet velocity and 
to the nozzle diameter; then Weber
21
 expanded the Rayleigh construct including a 
relation between an optimal wavelength for the jet break-up formation and the 
rheological characteristics of the extruded solution (II, III): 
 
          (II) 
 
          (III), 
 
moreover Branderberger and Widmer
22
 showed the correlation between the droplet 
diameter dD with wavelength and jet diameter (IV): 
 
   (IV); 
 
 is the wavelength, vJ is the jet velocity, f the frequency, opt is the optimal 
wavelength, dN is the diameter of the nozzle,  is the dynamic viscosity,  is the density 
and  is the surface tension. 
 
 
 
   Chapter 3                                                                           Chitosan/TPP microparticles 
 
85 
 
 
 
Figure 3-2. Droplet formation using a vibrating nozzle; the images on the right, precisely, are droplets 
formed by two immiscible solutions (adapted from Heinzen et al 
19
). 
 
3.3 Experimental section 
3.3.1 Materials 
Pentasodium triphosphate (Fluka), 1N hydrochloric acid, 1N sodium hydroxide 
(Aldrich), glacial acetic acid (VWR BDH Chemicals), sodium chloride (VWR BDH 
Chemicals), polysorbate 20 (Tween 20), fluorescein isothiocyanate-dextran 500000 
(FITC-dextran) (Fluka) and, 98% sulfuric acid (Fisons Scientific Equipment) were used 
as received. Chitosan (“low MW”: Cat. No. 448869, Aldrich) was used after 
purification as described in the paragraph 2.3.3. Chitosan, low molecular weight 
(Aldrich) was used after purification. Double distilled Milli-Q water was produced 
using in series an ELGA Docking Vessels DV35 and a Milli-Q Gradient A10 System. 
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3.3.2 Physicochemical characterisation 
The chitosan microparticles were produced using an Inotech encapsulator IE-50 R 
(Fig. 3-1). It was equipped with a pulsation unit and a nozzle that allows the formation 
of the jet break-up, essential for the beads formation. The encapsulator could be 
equipped with two different nozzles, one with an overture of 300 and the other one of 
200 micron. 
Two microscopes were used to assess the shape and the dimension of the 
microparticles: the inverted microscope Olympus CKX41, equipped with a tilting and 
trinocular head options and a pre-aligned phase contrast slider that has an alternative 
annulus for 4x magnification, and a bright field position; the stereo-microscope 
Olympus SZ61, equipped with two separate eyepieces in order to observe the 
tridimensionality of the objects. The digital camera Olympus DP12-2 was used to 
record the images of the microparticles. ImageJ was the program used to process the 
images recorded with the digital camera. A Perkin Elmer LS55 luminescence 
spectrometer was used to detect fluorescence in the release tests. 
 
 
Figure 3-3. Inotech® encapsulator IE-50 R. 
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3.3.3 Preparation of chitosan-TPP microparticles by ionotropic 
gelation 
The purified chitosan was dissolved in a 0.1M HCl solution and left in stirring for 2 
hours; several solutions were prepared at different concentrations. The pH was 
corrected with 1N NaOH to the wanted values. Separately, the TPP was dissolved in 
Milli-Q water and the pH corrected to the wanted values using 1N HCl. The ionic 
strength was buffered to 0.15M with NaCl, in both chitosan and TPP solutions, in all 
the experiments. 
For all the tests, the chitosan solution was placed in a syringe connected with the 
encapsulator and the TPP solution was placed as a hardening bath under the vibrating 
nozzle. Chitosan solution was extruded through the nozzle (200 or 300 μm in diameter) 
and was broken down into homogeneous droplets that gel in contact with the stirred 
hardening bath (Fig. 3-2). The lateral amplitude of the nozzle was fixed to 7, in the 
apparatus the possible values range between 1 and 7. The electrostatic charge was 
applied in order to spread the drops and avoid drop coalescence after the ejection from 
the nozzle, in this way the jet-break up was improved. Additionally, the distance 
between the nozzle and the bath was an important parameter which was optimized. The 
parameters and their range are shown in table 3-1. 
Once the microparticles were produced, they were drained and size and shape were 
evaluated with the microscopes. 
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Table 3-1. Parameters under investigation during the experiments 
Parameter
Nozzle
Frequency
Amplitude
Pump
Height
Charge
[CS]
[TPP]
CS pH
TPP pH
Meaning
Aperture size
Frequency of the vibration 
of the nozzle
Amplitude of lateral vibration 
of the nozzle
Polymer pumping rate
Distance between the nozzle and
the hardening bath
Electrostatic charge applied to
the jet break-up
Chitosan concentrations
TPP concentrations
Chitosan pH value
TPP pH value
Range
200, 300 μm 
800-1200 Hz
7
0.076-2.310 g/sec
29.5 cm
0.76-2.31 kV
0.5, 1.0, 1.5, 2.0 %w/v
1.25, 2.50, 3.68, 5.00 %w/v
2, 4, 5, 5.5, 6
4, 5, 5.5, 6, 7
 
h2
h1
ν (frequency) and electrostatic 
charge
q (flux)
µ 
(viscosity)
D 
(nozzle 
diameter)
h3
(surf. tens.)
d 
(particle 
diameter)
Hardening
 
 
Figure 3-4. Parameters that influence the production of monodisperse microparticles. 
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3.3.4 Tests of release 
Three types of microparticles with the best standard deviation were used for the tests of 
release. Dextran 500′000 Fluorescein isothiocyanate conjugate was used in the 
experiments; it was dissolved in the chitosan solution at a concentration of 90µg/mL 
prior the extrusion, the flow rate was fixed to 0.052g/sec. The beads did not show any 
type of physical change from the ones used as a blank without FITC-dextran. The 
releasing of FITC-dextran was monitored by using the luminescence spectrometer 
(λex=492 nm; λem=518 nm) for a range of time of 24 hours. 
 
3.3.5 Beads stability 
Chitosan/TPP complexes are not resistant to strong acid conditions; these tend to swell 
in acidic solution and start to dissolve in a solution with a pH value below 2.5
23
. In 
order to evaluate the stability, one optimised system of microparticles were prepared 
and shared in five vials; these were centrifuged and the supernatant (TPP solution) was 
removed, the beads were weighed and placed in different solutions (40 mL) at different 
pH values (0.7, 2.1, 3.0, 4.2, 5.7); the correction of the pH in the new solutions was 
performed using 1M HCl; the beads were left on the mixer at speed of 72 rpm for 72 
hours. The vials were centrifuged and the supernatant removed (with eventual 
chitosan/TPP in form of debris), the beads collected at the bottom of the vials were 
washed with distilled water until the pH of the solution was 7. The samples were 
freeze-dried and, soon after, the remnants microparticles weighed. The beads stability is 
quantified in degradation percentage using the following formula: 
weight before exp. – weight after exp.
weight before exp.
100.Degradation %  = 
. 
 
3.4 Result and discussion 
3.4.1 Preparation 
The encapsulation system produces beads based on laminar jet break-up induced by 
applying a sinusoidal frequency with defined amplitude to the nozzle. The top plate 
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contains a feed-line connected to a syringe or hydraulic polymer reservoir and a nozzle 
which can have a diameter in the range of 50-1000 µm. This nozzle is connected via 
steel or poly(tetrafluoroethylene) (PTFE) membrane to an insulated vibrating device 
containing rubber mounts which avoid the generation of resonance frequencies in the 
system. 
The target was the production of chitosan monodisperse microparticles linked with TPP 
and the range accepted was 300-600 µm; several preliminary tests were executed in 
order to optimize the complexation.  
Concentration and pH. For spherical and monodisperse beads, the gelation kinetics 
was a determinant factor; this property could be enhanced by increasing the 
concentration of the reagents, by modulating the temperature or, if this influence the 
number of charges, the pH values. Higher concentration of the two partners means 
higher concentrations of both negative and positive charges and therefore quicker 
reaction and higher cross-link density in the final material. Concentrations need 
therefore to be maximised. On the other hand, increasing concentration implies an 
increase in viscosity, which is detrimental to the process of drop formation (in the 
liquid that is extruded from the nozzle) or of bead dispersion (in the liquid that accepts 
the drops). 
In preliminary experiments, with a simple dropping of chitosan in TPP at pH=5 for 
both the solutions, which provides a good charge density on both polycation and 
polyanion, several concentrations were used to qualitatively assess the optimum range. 
Nozzle. For homogenous bead production the quality of the nozzle’s drilled sapphire 
disc is the most important parameter. The diameter of the beads is double the nozzle 
aperture and the range can be modified by about 20% by varying jet velocity, 
vibration frequency or applying an electrostatic charge
24
. The method used here was 
executed in an aqueous environment and under mild conditions. 
 
3.4.2 Results and characterization 
A first set of preliminary experiments were produced in order to choose the right 
parameter values and begin a more in deep research of the best type of microparticles. 
In table 3-2 there is a list of values used and the results obtained in terms of 
complexation and shape: 
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Table 3-2.  Preliminary experiments, factors and responses; VS=very slow, S=slow, G=good, D=debris, 
Sp=spherical, I=irregular. 
 
Factors Responses
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1
2
3
4
5
6
7
8
9
10
11
12
300
300
300
300
300
300
300
300
200
200
200
200
0.5
1
1.5
2
1.5
1.5
1.5
1.5
1.5
1.5
1.5
1.5
3.68
3.68
3.68
3.68
3.68
3.68
3.68
3.68
3.68
3.68
3.68
3.68
5
5
5
5
4
5
5.5
6
4
5
6
7
5
5
5
5
4
5
5.5
6
4
5
6
2
0.100
0.100
0.070
0.100
0.139
0.139
0.139
0.139
0.077
0.077
0.077
0.077
0.84
0.84
0.84
2.31
0.92
0.92
0.92
0.92
0.76
0.76
0.76
0.86
1000-1200
1000-1200
500-600
800-1000
500-600
500-600
500-600
500-600
1075
1075
1075
1075
VS
S
G
G
G
G
G
G
G
G
G
G
D
D
Sp
Sp
Sp
Sp
Sp
Sp
I
Sp
Sp
Sp
 
 
In all the experiments the flow rate was kept lower than 0.140 g/sec, since a higher 
value gave always formation of non spherical shaped microparticles. Complexation in 
particulates always occurred, except for chitosan concentrations below 1% in weight.  
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Figure 3-5. Experiments 1 to 4 (see table 3-2). In the first column there is no magnification, in the 
second and third column the magnification is 10X. 
 
 
Figure 3-6. Experiments 5 to 8 (see table 3-2). There is no magnification in the first column, in the 
second column the magnification is 4X meanwhile in all the others is 10X. 
 
   Chapter 3                                                                           Chitosan/TPP microparticles 
 
93 
 
 
Figure 3-7. Experiments 9 to 11 (see table 3-2). In the first column the magnification is 4X, in the 
second and third columns the magnification is 10X, in the last column is 40X 
 
The most monodisperse microparticles after the first sequence of experiments (Fig. 3-8) 
had a diameter between 400 and 750 μm; these substantial differences from the other 
samples were due to the change in nozzle diameter of the encapsulator and to the value 
of flow rate fixed to 0.077g/mol. 
 
 
Figure 3-8. Experiment 12 (see table 3-2). The magnification is 40X. Here two photos are superimposed, 
one with the beads and the other one with the hemocytometer (device usually used to count the cells and 
evaluate the dimensions).  
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A second set of experiments were performed in order to decrease further the size of the 
microparticles. It was still focused on the optimization of concentrations and pH values; 
additionally the Tween 20 was used in some of these experiments as a wetting agent in 
order to lower the surface tension and to decrease the interfacial tension between the 
droplet of chitosan and the hardening bath. In the following table and graphs are 
exposed all the variables and the results obtained. 
 
Table 3-3. Factors used in the second lot of experiments. The nozzle used has a diameter of 200 µm, 
charge voltage 0.86 kV, frequency 1075 Hz and flow rate 0.077 g/sec. 
Factors Responses
E
x
p
er
im
en
t
n
u
m
b
er
[C
S
] 
(w
t.
%
)
C
S
 p
H
[T
P
P
] 
(w
t%
)
T
P
P
 p
H
[T
w
ee
n
] 
(w
t%
)
n
. o
f 
b
ea
d
s 
In
 t
h
e 
co
u
n
t
S
iz
e 
(µ
m
)
±
S
D
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
1
1
1
1
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1
1
1
1
1
1
1
0.5
0.5
0.5
1
1
1
1.5
1.5
1.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
2.5
1.25
2.5
5
1.25
2.5
5
1.25
2.5
5
4
4
5
5
5.5
5.5
6
6
7
8
7
8
7
7
7
7
7
7
7
7
7
4
4
5
5
5.5
5.5
6
6
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5.5
5.5
4
4
4
4
4
4
4
4
4
0
1
0
1
0
1
0
1
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0
1
1
0
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0
0
0
0
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80
80
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--
--
--
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80
80
80
80
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653
586
563
682
620
632
526
479
662
684
--
--
--
413
281
402
522
555
497
165
148
147
117
135
103
102
121
55
85
145
117
--
--
--
79
44
51
131
150
85
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Figure 3-9. Experiments 1 to 12 (second set, see table 3-3). The dispersion of the microparticles is 
represented by colour, the darker appear circle the better is the dispersion; the larger will appear the size 
of the circles in the graph and the smaller correspond the microparticles produced; thereby the darker in 
colour and the larger in circle size are the best in the tests. 
 
The use of the Tween 20 did not imply any difference in bead’s formation, 
evidently the surface energy of the droplets and of the hardening bath did not change 
sufficiently with a concentration of the 1%wt (Fig. 3-9). The microparticles dispersion 
is satisfactory when the pH of the hardening bath is 6 or higher. During the beads 
formation the hydrochloric acid in the chitosan droplets is displaced by the TPP, which 
diffuse inside the droplets of chitosan and provoke the gelation, this process happen 
faster when the pH of the TPP solution is higher. A chitosan pH below 6 was necessary 
to obtain a uniform jet break-up, and the couple of pH 4(CS)-7(TPP) was the one gave 
better results. 
Finally, in the set of experiments 13-21 (Fig.3-10), once fixed the pH of the 
solutions, the concentrations were optimized. At higher value of concentration of TPP 
in the hardening bath results a quicker gelation and a more monodisperse 
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microparticles. The best samples were obtained with a concentration of chitosan of 
1%wt and concentrations of TPP higher than 2.5% in wt. 
  
 
 
Figure 3-10. Experiment 13 to 21 (second set, see table 3-3). The dispersion of the microparticles is 
represented by colour, the darker appear circle the better is the dispersion; the larger will appear the size 
of the circles in the graph and the smaller correspond the microparticles produced; thereby the darker in 
colour and the larger in circle size are the best in the tests. 
 
3.4.3 Tests of release 
Three types of microparticles were chosen (ex. 9, 10, 18, see Table 3-3) since they were 
the least disperse in terms of size; a large, non-ionic fluorescently-labelled 
macromolecule, FITC-dextran, was used to qualitatively assess the mesh size of the 
chitosan matrices by the means of fluorimetry: dextran has no electrostatic interactions 
with either TPP or chitosan, and it is completely water-soluble, therefore its possible 
retarded release is solely due to the mesh size of the chitosan-TPP network. FITC-
dextran was dissolved in the chitosan solution is therefore supposed to be 100% 
entrapped in the bead structure at the gelation. It is apparent (Figure 3-11) that the 
FITC-dextran is quickly released from all the beads. However, while particles 9 show a 
substantially quantitative release within the first minute (the drift in fluorescence 
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intensity is due to experimental problems, possibly evaporation of the solution), the 
release of particles “10” and even more particles “18” shows a first-order-like 
behaviour. One should take into account the sample “10” particles are prepared using a 
higher pH of the TPP solution, which may cause some chitosan-chitosan aggregation, 
which would increase the tortuosity of the matrix, while the increased concentration of 
TPP used in the preparation of sample “18” should increase the cross-link density of the 
matrix, thus decreasing its mesh size. We can therefore conclude that the effect of 
increased cross-link density of sample “18” seems to overwhelm that of increased 
tortuosity of sample “10”. 
Furthermore, since dextran of MW=500,000 g/mol has an hydrodynamic radius of 
about 16 nm
25
, it is reasonable to think that sample “18” has a mesh size in the order of 
magnitude of tens of nm. 
 
 
Figure 3-11. The best three samples (2
nd
 set of experiment) were used in the experiment of release for a 
run of 24 hours. Within the first 50 minutes the 80% of FITC-dextran is released in the media. 
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3.4.4 Beads stability 
The beads stability was performed suspending the optimised microparticles in different 
solutions, each of them having different pH values. The damaging of the microparticles 
depended on the penetration of the medium, successive hydration, and dissolution of 
the matrix.  Swelling and then degradation is sensitive to the pH, in the following table 
the variables and percentage of degradation are expressed after the execution of the 
experiment: 
 
Table 3-4. The table shows the parameters in the experiments of stability and the percentage of 
degradation. The experiment lasted 72 hours. The theoretical starting dry weight is calculable since the 
water content in the beads was the 74% of the total weight; this percentage value was confirmed in the 
preliminary experiment. 
 
 
 
From the results of the experiment was deducible that, when the microparticles were 
dipped in solutions with pH values lower than 3, these started to break themselves; the 
lower was the pH value and the higher was the degree of dissolution. 
 
3.5 Conclusion 
The results obtained were really promising, optimized and monodisperse beads were 
produced with the Inotech® encapsulator; the use of this device allows working in 
sterile conditions and the production of microparticles was performed using limited 
quantities of materials; several active principles can be loaded with a yield of 
entrapment of 100%, the single drawback to avoid is the rapid degree of release. 
Furthermore, tests on the mechanical properties must be executed and the degree of 
crosslinking has to be known, instruments like rheometer can be used for the first 
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purpose. In the next steps, the loading of hydrophobic molecules with different MWs 
could be tested and moreover the embedding of living cells could be a target to follow 
too. A method for drying and store the beads without damage them permanently  can be 
studied, to maintain the structure intact could be the use of alcohol exchange and CO2 
supercritical drying
26
, this process was already executed with alginate/chitosan 
microcapsules and gave good results. 
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4. Conclusion 
The aim of the entire project was to use chitosan and sodium triphosphate for producing 
structures able to form matrixes of limited dimensions in a reproducible fashion. Nano- 
and micro-vehicles were fabricated by ionotropic gelation. 
 
Efficient complexation in nanoparticles formation 
The first achievement was the purification and the characterization of the chitosan, 
in terms of average molecular weight and degree of deacetylation had to be known in 
each step of the above mentioned process in order to produce reproducible materials. 
The investigation regarding the complexation between chitosan and sodium 
triphosphate focused on optimizing the interplay between nucleation and growth of the 
nanoparticles in the two mixed solutions. When the mixing was executed with different 
pH (acid for chitosan and slightly basic for TPP) larger aggregates were produced. This 
confirmed that there was a kinetic control of the complexation, chitosan complexation 
with TPP happened faster than proton exchange or at least with a comparable kinetics. 
Moreover, analyzing the ageing of the colloidal suspensions, it was noticed that the 
systems evolved with a resultant increase in pH, this could be explained since a 
complexed chitosan possesses ammonium ions with different pKa values respect to a 
non-complexed chain of polymer, consequently the nanoparticles during time 
sequestrate protons from the solution. 
The coating procedure of the nanoparticles, based on the electrostatic interactions 
between the positively charged the chitosan nanoparticles and the polyanion hyaluronic 
acid (HA), had to be fast in order avoid flocculation of particles with negligible or zero 
zeta potential produced at intermediate stages during the complexation; having this in 
mind, a large excess of coating agent (HA) was used respect to the amount of 
nanoparticles,. The degree of swelling was highlighted being dependent from the ionic 
strength, and the feasibility of the encapsulation of nucleic acid oligomers was 
evaluated as well.  
In in vitro cellular tests on macrophages, the nanoparticles, both coated and 
uncoated, showed principally a clathrin-mediated uptake, in support of this thesis 
several effectors were used; additionally the coated ones resulted much less toxic than 
the uncoated nanoparticles, this was due to the high compatibility of the hyaluronic 
acid. 
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Chitosan microparticles 
The parameters related to the Inotech® encapsulator were influencing the shape and 
the dimensions of the beads but the optimization of the beads was reached subsequent 
to an exhaustive study on the kinetic of complexation between chitosan and TPP. The 
triphosphate had to be in condition to enter deeply in the chitosan droplets and bridge 
with the free primary ammines of the chitosan, additionally the complexation happens 
simultaneously with the pH equilibrium of the two phases. Once formed, the 
microparticles demonstrated to last for a long period of time; however more studies 
regarding the ageing and the degree of crosslinking must be conducted. 
The main use of these microparticles could be the entrapment of cells with a 
consequent positioning in a biological environment. The control of the degree of 
crosslinking will be important in the facilitating the survival of the cells, protecting 
them from the immunosystem activation and allowing the permeation of nutrients and 
the clearance of waste materials of the cells. In conclusion the modulation of the 
bioerodibility of the beads in situ must be evaluated in order to avoid quick matrix 
degradation. 
This is a simple technique for the embedding of active principles based on 
biodegradable and cost-effective raw materials, ready to be scaled up in mass 
production. 
 
 
 
 
